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Abstract 
Current hypotheses suggest that a disrupted antiprotease-protease balance results in 
structural tissue damage in cystic fibrosis (CF) lung disease. Clinical studies identified 
elevated neutrophil elastase (NE) levels as risk factor for the onset of structural lung 
damage in young CF patients. A recent study reported that levels of NE-activated matrix 
metalloproteinase (MMP)-9 correlated with the progression of bronchiectasis in CF 
patients. Studies in mice with lung-specific overexpression of the β subunit of the 
epithelial Na+ channel (βENaC-Tg) confirmed a crucial contribution of NE activity to CF-
like lung disease. However, NE deletion only partially reduced structural lung damage, 
i.e. emphysema, suggesting that additional factors contribute to tissue destruction in 
βENaC-Tg mice.  
The present study investigates the pathogenic role of MMP-9 in βENaC-Tg mice. Similar 
to CF patients, MMP-9 protein levels were elevated in bronchoalveolar lavage (BAL) fluid 
of βENaC-Tg mice as detected by gelatin zymography. To determine the contribution of 
MMP-9 to the pathogenesis of βENaC-Tg mice, mortality, pulmonary inflammation, 
transcript levels of mucins, distal airspace enlargement and soluble MMP-9 activity in 
BAL fluid were studied in WT, Mmp9-/-, βENaC-Tg and βENaC-Tg/Mmp9-/- mice. 
Additionally, measurement of lung function in NE or MMP-9 deficient βENaC-Tg mice 
enabled the comparison of the individual influence of the respective protease on lung 
tissue mechanics.  
Inflammatory cytokines and neutrophil chemoattractants were elevated in βENaC-Tg 
mice and not altered in BAL fluid of βENaC-Tg/Mmp9-/- mice. In addition, pulmonary 
leukocyte infiltration, mucin expression and goblet cell metaplasia were not dependent 
on MMP-9 and elevated to similar levels in βENaC-Tg and βENaC-Tg/Mmp9-/- mice. Lung 
volume measurement and morphometric quantification of distal lung histology showed an 
increased emphysema severity in βENaC-Tg mice which was not reduced in βENaC-
Tg/Mmp9-/- mice.  Free soluble MMP-9 activity could not be detected in BAL fluid neither 
of βENaC-Tg mice nor of littermate controls. Increased concentrations of tissue inhibitor 
of matrix metalloproteinases (TIMP)-1 as main endogenous MMP-9 inhibitor indicate an 
intact antiprotease-protease balance in BAL fluid of βENaC-Tg mice. Lung function 
testing revealed no improvement of static compliance, inspiratory capacity or tissue 
elastance by Mmp9 deletion in βENaC-Tg mice. The assessment of lung function 
displayed a significant amelioration of these parameters in βENaC-Tg/NE-/- compared to 
βENaC-Tg mice. According to these results, preclinical trials were performed targeting 
NE with the small molecule inhibitor sivelestat to test the effect on disease development 
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in newborn βENaC-Tg mice. Systemic sivelestat delivery by intraperitoneal injections 
reduced airway mucus obstruction but did not affect leukocyte infiltration or emphysema 
severity in two week-old βENaC-Tg mice compared to vehicle controls.   
In summary, the analysis of MMP-9 deficient mice suggests that MMP-9 is not crucial 
factor in the pathogenesis of βENaC-Tg mice. This may be related to balanced 
antiprotease levels in the lungs of βENaC-Tg mice, which are frequently depleted in CF 
patients. Therefore, it is difficult to deduce from the current studies the pathogenic 
potential of MMP-9 in more severe stages of CF lung disease. In contrast to Mmp9 
deletion, NE deficiency improved lung function in βENaC-Tg mice. The preclinical trials 
with sivelestat showed that NE inhibition was insufficient to reproduce the results of NE 
deletion in βENaC-Tg mice. Thus, further treatment studies are needed using 
compounds with improved pharmacokinetic properties that enable effective NE inhibition 
in pulmonary tissue.  
  Zusammenfassung 
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Zusammenfassung 
Gegenwärtigen Hypothesen zufolge kann ein unausgeglichenes pulmonales 
Antiprotease-Protease Gleichgewicht strukturelle Gewebeschäden bei Patienten mit 
Mukoviszidose (CF) auslösen. In klinischen Studien wurde festgestellt, dass eine 
erhöhte Neutrophile Elastase (NE) Aktivität ein Risikofaktor darstellt für die Entstehung 
von strukturellen Lungenschäden bei jungen CF Patienten. In einer kürzlich 
veröffentlichten Studie wurde berichtet, dass die Konzentration von NE-aktivierter Matrix-
Metalloproteinase (MMP)-9 mit dem Fortschreiten von Bronchiektasen bei CF-Patienten 
korrelierte. Studien an Mäusen mit lungenspezifischer Überexpression der β-Untereinheit 
des epithelialen Na+-Kanals (βENaC-Tg) bestätigten einen entscheidenden Beitrag von 
NE Aktivität zur CF-ähnlichen Lungenerkrankung. NE Deletion reduzierte jedoch nur 
teilweise die strukturellen Lungenschäden, d.h. das Emphysem, was darauf hindeutet, 
dass zusätzliche Faktoren zur Gewebezerstörung in βENaC-Tg-Mäusen beitragen. 
Die vorliegende Studie untersucht die pathogene Rolle von MMP-9 in βENaC-Tg-
Mäusen. Ähnlich wie bei CF-Patienten wurden erhöhte MMP-9-Proteinspiegel in 
bronchoalveoläre Lavage (BAL)-Flüssigkeit von βENaC-Tg-Mäusen festgestellt. Um den 
Beitrag von MMP-9 zur Pathogenese von βENaC-Tg-Mäusen festzustellen, wurden 
Mortalität, pulmonale Entzündung, Transkriptspiegel von Mucinen, Schweregrad des 
Emphysems und lösliche MMP-9-Aktivität in BAL-Flüssigkeit von WT, Mmp9-/-, βENaC-
Tg und βENaC-Tg/Mmp9-/- Mäusen untersucht. Zusätzlich ermöglichte die Messung der 
Lungenfunktion in NE- oder MMP-9-defizienten βENaC-Tg-Mäusen den Vergleich des 
individuellen Einflusses der jeweiligen Protease auf mechanische Eigenschaften des 
Lungengewebes. Es wurden erhöhte Konzentrationen von Entzündungs-Cytokinen und 
Neutrophilen-Chemokine in βENaC-Tg-Mäusen gemessen, die in der BAL von βENaC-
Tg/Mmp9-/- Mäusen nicht verändert waren. Darüber hinaus zeigten Leukozyteninfiltration, 
Mucinexpression und Becherzellmetaplasie keine Abhängigkeit von MMP-9 d.h. war 
unverändert in βENaC-Tg und βENaC-Tg/Mmp9-/- Mäusen. Die Messung des 
Lungenvolumens und Morphometrie der distalen Lungenhistologie zeigten bei βENaC-
Tg-Mäusen einen höheren Schweregrad des Emphysems, der in βENaC-Tg/Mmp9-/- 
Mäusen nicht reduziert war. Darüber hinaus konnte keine freie lösliche MMP-9-Aktivität 
in der BAL-Flüssigkeit weder von βENaC-Tg-Mäusen noch Wurfgeschwistern 
nachgewiesen werden. Erhöhte Konzentrationen von „tissue inhibitor of 
matrixmetalloproteinases“ (TIMP)-1, als wichtigster endogener MMP-9-Inhibitor, deuten 
auf ein intaktes Antiprotease-Protease Gleichgewicht in der BAL Flüssigkeit von βENaC-
Tg-Mäusen hin. Lungenfunktionsmessungen zeigten keine Verbesserung der statischen 
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Compliance, der inspiratorischen Kapazität oder der Gewebeelastizität durch Mmp9 
Deletion in βENaC-Tg-Mäusen. Die Untersuchung der Lungenfunktion in βENaC-Tg/NE-/- 
Mäusen zeigte eine signifikante Verbesserung dieser Parameter im Vergleich zu βENaC-
Tg-Mäusen. Basierend auf diesen Ergebnissen wurden präklinische Studien mit dem 
niedermolekularen NE Inhibitor Sivelestat durchgeführt, mit dem Ziel den Effekt auf die 
Entwicklung des Krankheitsheitsgeschehen in neugeborenen βENaC-Tg-Mäusen zu 
untersuchen. Die systemische Abgabe von Sivelestat durch intraperitoneale Injektionen 
reduzierte die Atemwegsobstruktion durch Mukus, verminderte jedoch nicht die 
Infiltration durch Leukozyten oder den Schweregrad des Emphysems in zwei Wochen 
alten βENaC-Tg-Mäusen im Vergleich zu Kontrolltieren. 
Zusammenfassend lässt die Analyse von MMP-9-defizienten Mäusen darauf schließen, 
dass MMP-9 kein entscheidender Faktor in der Pathogenese von βENaC-Tg-Mäusen ist. 
Dies kann mit den austarierten Antiprotease-Spiegeln in den Lungen von βENaC-Tg-
Mäusen zusammenhängen, die bei CF Patienten häufig verringert sind. Daher ist es 
schwierig, aus den aktuellen Studien das pathogene Potenzial von MMP-9 in 
schwereren Stadien der CF Lungenerkrankung abzuleiten. Im Gegensatz zur Mmp9-
Deletion verbesserte das Fehlen von NE die Lungenfunktion in βENaC-Tg-Mäusen. Die 
präklinischen Studien mit Sivelestat zeigten, dass die erzielte NE-Hemmung 
unzureichend war und die Ergebnisse der NE-Deletion in βENaC-Tg-Mäusen nicht  
reproduziert werden konnten. Daher sind weitere Behandlungsstudien erforderlich, bei 
denen Verbindungen mit verbesserten pharmakokinetischen Eigenschaften verwendet 
werden, die eine wirksame NE-Hemmung im Lungengewebe ermöglichen. 
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1 Introduction 
1.1 Cystic fibrosis 
Cystic fibrosis (CF) is a disease with autosomal recessive inheritance caused by more 
than 2000 documented mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) Cl- ion channel [27, 68, 133]. In populations with European descent 
around 4 % of all individuals carry a mutated allele causing a prevalence of 1 : 2,500 and 
a total of ~70,000 CF patients worldwide [27, 90]. 
1.1.1 Early pathophysiology of cystic fibrosis lung disease 
Loss of CFTR functions lead to the production of altered secretions in all exocrine 
glands. Among them, pulmonary airway epithelia are severely affected and the resulting 
chronic lung disease causes > 80 % of the CF-associated mortality [112]. CFTR is highly 
expressed in submucosal glands and also in airway epithelium by ionocytes, ciliated, 
club and goblet cells [65, 103]. CFTR is permeable for a wide range of anions, but 
physiologically relevant is the conductivity for Cl-, HCO3
- , glutathione (GSH), I- and SCN- 
ions [83]. Airway epithelia permit a paracellular water transport to a decreasing degree in 
proximal direction of the conducting airways. Airway epithelia are covered by a ~ 10 µm 
thick airway surface liquid (ASL) layer which can be further divided in the periciliary layer 
(PCL) and the mucus layer [16]. Normal mucus is transported cranially from lower 
airways propelled by coordinated ciliary beating within the PCL of airway epithelial cells 
or by cough. Both ways enables the clearance of cellular debris, pathogens and other 
irritants from the lungs [38, 179]. 
The exact pathogenesis of CF lung disease is unknown. According to current hypothesis, 
the ASL height is particularly dependent on the conductance of the epithelial Na+ 
channel (ENaC) and CFTR [38, 129]. Functional CFTR inhibits ENaC and thereby 
critically determining ASL height. CFTR mutation abrogates Cl- secretion in airway 
epithelia and promotes ENaC-mediated Na+ hyperabsorption. Because ion transport is 
coupled with water flow, ASL remains isotonic but is depleted in CF airways [91, 93].  
Mucus normally consists of 97 % water and 3 % solids which are composed of ions, 
mucins in particular MUC5B and MUC5AC, non-mucin proteins, lipids and cellular debris 
[38]. In CF, airway mucus solids rise to >8 % largely due to volume depletion, elevated 
concentrations of MUC5B, MUC5AC and additionally presences of intracellular 
components in particular actin and DNA [38]. It has been proposed that the solute 
concentration rises in consequence of ASL liquid depletion until the osmotic pressure of 
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thickened visco-elastic mucus gels exceeds the osmotic pressure in the PCL which leads 
to a reduction of the PCL high and compression of cilia [16]. Consequently, impaired 
mucociliary clearance (MCC) results in chronic airway mucus obstruction [38]. Further, 
MCC is ineffective in removal of irritants from the lungs and mucus obstruction might 
cause hypoxic cell necrosis in airway epithelia [43]. In addition, CFTR dysfunction may 
directly affect hypoxic vasoconstriction thereby further aggravating lung perfusion-
ventilation mismatch and increasing systemic hypoxemia [146]. Necrotic cells may 
release intracellular pro-inflammatory cytokines, e.g. interleukin (IL)-1α [43]. In addition, 
intracellular proteins and nucleotides may signal as damage-associated molecular 
pattern (DAMPs), e.g. heat shock proteins, and trigger a sterile inflammation by 
stimulation of pattern recognition receptors (PRRs), e.g. toll-like receptor 4 (TLR4), on 
epithelial cells or macrophages [20]. Hypoxia, IL-1α and TLR mediated NF-κB activation 
induces the expression of MUC5AC and metaplasia to goblet cells i.e. mucin secreting 
cells derived from club cells [76, 174]. In contrast, MUC5B shows a constitutive 
expression and only a limited upregulation during inflammation [38]. In summary, the 
induced mucin hypersecretion by inflammatory stimuli aggravates airway mucus 
obstruction in CF lung disease [91]. 
1.1.2 Signs and symptoms at later stages of CF lung disease  
During the course of CF, lungs often become colonized by bacteria leading to chronic 
infection with intermittent exacerbations. Glycans of airway mucins may provide the 
substrate for some bacterial strains and hypoxia favors the growth of facultative 
anaerobic bacteria e.g. Pseudomonas (P.) aeruginosa [173]. Bacterial infection leads to 
the release of pathogen-associated molecular patterns (PAMPs) e.g. lipopolysaccharides 
(LPS) and chemoattractants e.g. formyl-Met-Leu-Phe (fMLF or also termed fMLP). In 
combination with an impaired MCC, this is thought to amplify the recruitment and 
activation of large numbers of leukocytes.  
Chronic inflammation, airway mucus obstruction, infection and exposure of epithelia to 
persistently activated leukocytes is thought to cause epithelial damage, aberrant tissue 
remodeling and destruction of extracellular matrix (ECM) [127, 159]. In CF patients, 
structural lung damage is present as widening of small bronchi, termed bronchiectasis 
[127]. A destruction of alveolar walls summarized as emphysema has been observed in 
older CF patients [144, 169]. These progressive and irreversible structural changes of 
tissue architecture may affect lung function. 
Lung function measurement of CF patients typically show an impaired expiratory airflow 
which is related to airway obstruction and/or a compromised elastic lung recoil [127]. The 
forced expiratory volume in one second (FEV1) is used to detect the changes in 
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expiratory airflow and is often expressed as % of predicted values (FEV1%). Reference 
values are calculated based on ethnic group, gender, height and age [55]. The lung 
volume change over a defined applied pressure difference is expressed as lung 
compliance and reflects the ability of a lung to expand or stretch. Typically, the 
compliance is highly elevated in emphysematous lungs and reduced in pulmonary 
fibrosis. In general, during a breathing cycle pressure and lung volume changes show a 
hysteresis during inspiration and expiration. Despite a matter of ongoing research, the 
energy dissipation responsible for hysteresis is thought to be related to a gradual 
opening of closed e.g. atelectatic alveoli during unfolding of alveolar tissue [37]. 
Atelectasis can arise from airway mucus obstruction  [120]. In addition, changes in 
surface tension during inspiration are discussed as cause for hysteresis. In conclusion, 
force is needed during inspiration which is not recovered during deflation [37].  
CF patients show a progressive decline in lung function as indicated by diminishing 
values for FEV1% predicted in lung function measurements. This decline starts early and 
accelerates with late childhood and may lead to respiratory failure [73, 112]. Ultimately, 
this necessitates lung transplantation in severe cases of CF and rendering lung disease 
the major determinant for the reduced life expectancy of approximately 37 years [112]. 
1.2 Role of neutrophilic inflammation in CF lung disease 
In CF lung disease, the dominant leukocytes are neutrophils. Neutrophil counts in 
sputum correlate inversely with FEV1 decline in CF patients [136]. This indicates an 
important role of neutrophils in the progression of CF lung disease. However, disease-
promoting mechanisms of neutrophils remain elusive. Neutrophils accumulate by a 
combination of an increased life span, a potentiated influx and also by a reduced 
clearance via MCC, cough or efferocytosis by alveolar macrophages [95, 107]. The 
increased influx is related to an increased generation of chemoattractant (see below) and 
life span of neutrophils was shown to be increased in response to exposure to bacterial 
products or to various cytokines which delays apoptosis [23, 95].  
1.2.1 Recruitment of neutrophils into the lungs and involved chemokines   
Although PRRs are also present on epithelial cells, tissue resident alveolar macrophages 
are considered to have a key role in the early inflammatory response as sentinel cells 
and by secretion of cytokines e.g. tumor necrosis factor α (TNF-α) and chemokines e.g. 
CXC chemoattractants to initiate an inflammatory response [154, 168]. In addition, IL-1 
receptor signaling may induce inflammatory chemokine expression [111]. 
CXC chemokines are diverse between species including humans and mice. In humans, 
CXCL8 or interleukin 8 (IL-8) is considered to be the major chemokine for neutrophils 
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[29]. In mice, two functional IL-8 homologues keratinocyte-derived chemoattractant (KC) 
(also named mCXCL1), macrophage inflammatory protein 2 (MIP-2) (also named 
mCXCL2) and additionally LPS-induced CXC chemokine (LIX, also named CXCL5) and 
murine specific lungkine (also named mCXCL15) mediate neutrophil recruitment into the 
inflamed respiratory tract [29, 100]. During inflammation KC and MIP-2 are primarily 
secreted by macrophages [28]. In contrast, lungkine is expressed by bronchial epithelial 
cells and major sources for LIX are platelets in the blood and during inflammation 
alveolar type II cells in lung parenchyma [100].  
Lungs differ from all other organs in terms of the site of infiltration. Neutrophils 
transmigrate mainly at pulmonary capillaries and not at post-capillary venules [34, 130]. 
Transmigration takes places preferentially at cell-cell borders where gaps are present or 
formed between intercellular junctions and the basement membrane is discontinuous.  
1.2.2 Neutrophil granule composition and role in infection 
CF patients suffer from recurrent bacterial infection and persistent colonization with 
opportunistic pathogens [127]. Granules are essential for the function of neutrophils to 
limit bacterial infections [25]. Four types of granules have been classified and are 
sequentially formed during neutrophil maturation: first, primary or azurophil granules are 
formed which contain neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) 
and neutrophil serine protease-4 (NSP4) [74, 119]. NE, PR3 and CatG are specifically 
expressed in neutrophils and stored as active enzymes. Secondary or specific granules 
contain the pro-form of collagenase pro-MMP-8. Pro-MMP-9 is present in a subfraction 
of specific granules and in particular in tertiary granules. Both granule types contain 
additionally gp91phox which is a critical subunit of the NADPH oxidase [25]. Of note, 
neutrophils express all proteases only during granulopoeisis in the bone marrow [9, 39]. 
Secretory vesicles as forth granule type contain various plasma proteins and represent a 
reservoir for membrane receptors for neutrophil adhesion and subsequent activation e.g. 
integrins CD11b-CD18, fMLP-receptor, gp91phox [9].  
The 4 granule types differ in their tendency to undergo exocytosis and follow a hierarchy 
corresponding to the sequence of their generation during granulopoeisis [25]. For 
example, during chemotaxis all of the secretory vesicles are released while only a minor 
fraction of azurophil granules is secreted. Specific and tertiary granules show an 
intermediate exocytosis rate.  
It is now accepted that a significant fraction of the secreted proteases remains bound to 
the surface of neutrophils apart from free soluble protease pool [122]. However, the 
function of the surface-bound protease activity in comparison to free soluble proteases 
remains unknown. NE binds the neutrophil surface via electrostatic interaction with 
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sulfated-proteoglycans while PR3 and MMP-9 interact with several transmembrane-
receptors [74, 157].  
The function of neutrophils as phagocytes is dependent on their granule content. 
Phagocytosis of bacteria triggers the fusion phagosomes with azurophil and in part also 
specific granules [25]. Bacteria are killed mainly by reactive oxygen species (ROS) 
generated by NADPH oxidase and also by proteases e.g. NE which cleaves bacterial 
membrane proteins [7, 164]. In addition, neutrophils are able to secrete their nuclear 
DNA in a process termed NETosis which represents an extracellular killing mechanism in 
particular for large, indigestible pathogens [11, 164]. During the formation of neutrophil 
extracellular traps (NETs) NE, PR3, CatG as well as MMP-9 are deposited together with 
nuclear DNA and other components e.g. histones [13]. Pathogens are trapped in NETs 
and killed by DNA itself and potentially by associated proteins, including CatG and NE 
[13, 54]. 
These bactericidal processes may also promote CF lung disease. ROS release and 
associated oxidative stress may cause a stiffening of the mucus gel by oxidizing mucins 
[177]. Additionally, DNA secretion during NETosis may alter mechanical properties of the 
mucus gel. The resulting changes in mucus rheology may impair MCC, favor chronic 
colonization with bacteria and worsen airway mucus obstruction [38]. 
1.3 Neutrophil-derived proteases as modulator of CF lung 
disease 
Chronic pulmonary inflammation is thought to cause or aggravate pathophysiological 
epithelial and structural alterations. These include goblet cell metaplasia, mucin 
hypersecretion, enlargement of bronchi and distal airspaces, i.e. bronchiectasis and 
emphysema, eventually leading to impaired lung function [91–93, 118]. In CF airways, 
the cell covering ASL contains high concentration of NE, PR3, CatG, MMP-8 and MMP-9 
[159]. These proteases may be secreted by neutrophils and are able to degrade a wide 
range of substrates either of microbial origin but also of different pulmonary tissues.  
1.3.1 Role of NE in CF lung disease 
Most ECM proteins are substrates but also several cytokines, opsonizing factors, ion 
channels and scavenger receptors are cleaved by neutrophil-derived proteases [29, 107, 
159]. The prolonged exposure to proteolytic activity can lead to epithelial and tissue 
damage during chronic neutrophilic inflammation. In particular, extracellular NE activity 
was shown to promote several key pathogenic processes that are associated with CF 
lung disease including impairing MCC, stimulating airway remodeling and potentiating 
inflammation [159].  
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Under physiologic conditions, NE activity is limited by intracellular compartmentalization 
and if secreted in airspaces by the presence of the endogenous antiproteases such as 
elafin (in humans but not present in mice), secretory leukocyte protease inhibitor (SLPI) 
and α1-antitrypin (A1AT) [74]. Elafin and SLPI are secreted locally by leukocytes and 
epithelial cells while A1AT is produced by hepatocytes and reaches the lung via the 
blood circulation [170]. With progression of CF lung disease high numbers of neutrophils 
accumulate in the lung that release their granules content [88, 149]. Over time, this is 
thought to overwhelm the antiprotease shield that protects lung tissue from proteolytic 
damage [159].  
A disrupted protease-antiprotease balance may cause a vicious cycle of tissue damage 
and further release of pro-inflammatory mediators. NE induces the expression of IL-8 in 
human airway epithelial cells. In mice, NE instillation increase KC levels in BAL fluid and 
stimulates the release of high-mobility group box 1 from macrophages which both act as 
neutrophil chemoattractants [52]. 
Although direct evidence is lacking several in vitro and ex vivo studies support the 
hypothesis that NE may alter epithelial function. NE was shown to cause cell detachment 
in primary airway epithelial cell cultures, decrease proliferation, induce apoptosis and 
impair wound closure even at low concentration as present in young CF patients [47, 
159]. Furthermore, in vitro studies showed that NE triggers cell cycle arrest, induces 
goblet cell metaplasia, enhances MUC5AC expression and mucin secretion and reduces 
ciliary motility in bronchial epithelial cells [2, 159].  
NE was shown to cleave and inactivate the ENaC inhibitor short palate, lung, and nasal 
epithelium clone 1 (SPLUNC1) [64]. Moreover, NE can also directly activate ENaC and 
degrade CFTR which all combined potentially aggravate airway obstruction and may 
impair epithelial regeneration in chronic inflammatory lung diseases [2, 74, 93].  
Resolution of inflammation is impaired in CF patients which in part might be attributed to 
increased protease levels. For example, phagocytosis of apoptotic cells by macrophages 
prevents the release of intracellular pro-inflammatory DAMPs, stimulates anti-
inflammatory cytokines and initiates resolution of inflammation [107, 158]. NE degrades 
the phosphatidylserine-receptor, thereby inhibits efferocytosis, provokes secondary 
necrosis which leads to a release of DNA, actin, proteases and promotes chronic 
inflammation [107, 159].  
Structural lung damage in CF patients is observed early as bronchiectasis and in older 
patients as mild form of emphysema [144]. In CF airways, a significantly higher number 
of NE and MMP-9 positive cells have been detected in lamina propria of ectatic bronchial 
walls [178]. Furthermore, abnormal and fragmented elastin fibers have been reported in 
lungs of CF patients [14]. As mentioned, NE can cleave several subepithelial ECM 
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components including elastin [159] and elevated NE activity coincided with increased 
levels of urinary desmosine which is a proteolytic elastin degradation product. ECM 
degradation and remodeling is thought to lead to aberrant epithelial regeneration and 
thereby causing ectatic bronchi. Alterations in mechanical properties of lung tissue can 
be assessed clinically by lung function measurement of patients.  
1.3.1.1 Correlation of NE levels with clinical parameters in CF lung disease 
CF patients with identical CFTR mutations may experience a different rate in progressive 
decline in lung function. Various inflammatory sputum biomarkers were assessed to 
predict progressive reduction in lung function. Prospective studies in young patients 
identified protease activity, in particular of NE and MMP-9, as a predictive marker for 
disease progression [48, 136].  
Increased levels of NE in bronchial secretions were identified as risk factor for the 
development of bronchiectasis and showed an association with deterioration of lung 
function in CF patients [136, 142]. This supports the hypothesis that NE has a crucial 
role in the pathogenesis of CF lung disease. In a recent study, NE activity in sputum 
supernatant and on surface of sputum neutrophils correlated best with FEV1% or the 
functional residual capacity, respectively [33]. The latter estimates the volume that 
remains in the lungs after expiration and may indicate the presence of bronchiectasis in 
CF patients.  
Elevated NE activity coincided with lower levels of its inhibitors. In particular, SLPI and 
concentrations of NE complexed with A1AT show a declining trend during disease 
progression in CF patients [136]. NE seems to have an important role in tilting the 
protease-antiprotease balance. It was shown to degrade SLPI and TIMP1, the major 
inhibitor of MMP-9 [157, 170]. Furthermore, NE may activate pro-MMP-9 while MMP-9 
cleaves A1AT suggesting a synergistic and potentiating activity of both proteases [46, 
85].  
1.4 Matrix metalloproteinase 9: structure, cellular sources, 
biochemistry and role in inflammation 
Several studies pointed out that MMP-9 is elevated in sputum or BAL fluid of CF patients 
[30, 48] and in vitro studies suggest an involvement in modulation of inflammation, 
wound healing and ECM remodeling [29, 115, 154, 157]. This suggests a contribution of 
MMP-9 in the pathogenic events of CF lung disease although a closer examination is 
lacking.  
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1.4.1 Activation, catalytic mechanism and substrate specificity are 
determined by distinct structural modules in MMP-9 
In general, proteases are enzymes which irreversibly hydrolyze the peptide bond of their 
protein substrate. This process is in most cases highly specific and often has various 
regulatory functions with proteolysis often marking a switch in a cellular response e.g. in 
apoptosis induction or initiates signaling cascades, for example in blood coagulation. 
Proteases are subdivided into 5 different classes based on their hydrolytic mechanism: in 
cysteine, serine and threonine proteases the respective amino acid sidechain acts as 
nucleophile to attack the peptide bond while in aspartic and metalloproteases an 
activated H2O serves directly as the reactive molecule [125]. Metalloproteases and 
serine protease are the two largest classes in mice and humans [113].  
MMPs are a major subfamily of metalloprotease which all form a complex with Zn2+ ions. 
Three histidine residues in the sequence HEXXHXXGXXH bind one Zn2+ ion to form the 
active center while glutamate serves as a base during catalysis [152]. According to the 
current model of MMP proteolysis, the hydrolytic cycle of a peptide bond starts with 
polarizing a water molecule by Zn2+. H2O then protonates the glutamate residue in the 
active center and the remaining hydroxide ion reacts with the peptide´s carbonyl C-atom 
to form a carboxyl group. The bound proton by glutamate is transfer to the secondary 
amine in the peptide bond and thereby cleaving the protein by rearrangement of covalent 
bonds (Figure 1.1) [40, 147]. The pH optimum of MMP-9 has been determined at near 
neutral values of ~7.5 [109]. 
All MMPs, except for MMP-23, are translated into inactive pro-forms i.e. zymogens. The 
pro-peptide covers the substrate binding cleft and a cysteine in the conserved “cysteine 
switch sequence” coordinates via its thiol group with the zinc ion to prevent the entry of 
water to the active center [147]. Under physiological conditions, the pro-peptide of MMP-
9 can be removed by trypsin and various other secreted MMPs e.g. MMP-2, 3 or 13. 
Additionally, plasmin, tissue kallikrein and neutrophil-derived serine proteases in 
particular NE and CatG were shown to cleavage-activate pro-MMP-9 [154, 157].  
Pro-MMP-9 has a molecular weight of 92 kDa and the active form 82 kDa although 
intermediate sizes can be present and further truncated forms have been reported. Also 
oligomers with a size > 200 kDa and hetero-complexes with neutrophil-gelatinase 
associated lipocalin (NGAL) in the range of approximately 130 kDa have been reported 
[157]. In addition, the actual weight might differ between individual molecules due to 
differences in glycosylation (see below). In vitro several reagents, e.g. 4-aminophenyl 
mercuric acetate (APMA), have been used to activate pro-MMP9 which all disrupt the 
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interaction of pro-peptide´s cysteine with Zn2+. Alternatively, renaturing unfolded pro-
MMP-9 results in activation of the enzyme [156].  
 
Figure 1.1: Model of the catalytic mechanism of MMPs. Initially, the zinc ion polarizes 
a water molecule (1.) which transfers a proton to glutamate in the active center. The 
scissile carbonyl bond is polarized by interaction with Zn2+. The hydroxide anion (2.) 
attacks the carbonyl C atom while the bound H+ is transferred to the scissile secondary 
amine in the peptide bond which results in a tetrahedral intermediate (3.). The peptide is 
cleaved by rearrangement of covalent bonds (4.) but stays bound to the enzyme. The 
product release is triggered by binding of a new water molecule and marks the rate 
limiting step in the proteolytic cycle (based on [40, 147]). 
The substrate specificity of MMP-9 is mainly determined by its S1’ pocket, by three 
fibronectin repeats that are inserted in the catalytic domain and by the C-terminal 
hemopexin domain which serves for binding of substrates (e.g. type IV collagen or 
fibronectin), of inhibitors and of cell surface receptors (e.g. integrins, CD44, Ku70/Ku80) 
[157][147]. A synonym for MMP-9 is gelatinase B, while gelatinase A refers to MMP-2, 
indicating their closely related structure and specificity.  
1.4.2 Cellular sources and regulation of MMP-9 activity 
In general, MMP-9 activity is regulated i) by transcription, ii) by zymogen activation and 
iii) by presence of endogenous inhibitors in particular TIMPs. The basal expression of 
Mmp9, in contrast to Mmp2, is very low in most cell types. Mmp9 transcription is highly 
induced by physical or chemical stress, by growth factors (e.g. EGF and VEGF), by 
cytokines (e.g. IL-1, TNF-α), by hormones (e.g. vitamin D3), by bacterial products (e.g. 
LPS) and by cell-matrix adhesion (e.g. in macrophages by integrin-fibronectin/collagen) 
[22, 154]. 
Various lung parenchymal and lung resident cell types may express MMP-9 upon 
induction. These include: fibroblasts, airway smooth muscle cells, endothelial cells, 
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bronchial epithelial cells, alveolar type II cells, alveolar macrophages, dendritic cells, 
monocytes, eosinophils, immature neutrophils and lymphocytes including T and B cells 
[110, 154, 157]. Neutrophil-derived MMP-9 is subject to an additional regulatory 
mechanism: the stimulation of granule secretion. Hypoxia as present locally in 
obstructive lung diseases was shown to upregulate neutrophil degranulation [61]. Of 
note, neutrophils are able to secret A1AT, while MMP-9 is released without simultaneous 
liberation of its main inhibitor TIMP1. Therefore, chronic neutrophilic lung disease likely 
show increased levels of unopposed MMP-9 activity.  
In the blood the general protease inhibitor α2-macroglobulin restricts MMP activity. In 
other tissues, TIMPs limit MMP activity: TIMP1-4. Although all TIMPs inhibit MMP-9, 
TIMP1 has the highest affinity and additionally its expression is induced by similar stimuli 
as for Mmp9 [22]. Consequently, most of those cells secreting MMP-9, simultaneously 
release TIMP1 which contributes to a protease-antiprotease balance in the affected 
tissue [22, 156]. TIMP1 inhibits MMP activity by tight binding to various sites of the 
protease. TIMP1 can complex the catalytic Zn2+ and occupy the substrate binding site 
but also associate with C-terminal domains of pro- and active MMP-9 [106, 154].  
 
1.4.3 Role of MMP-9 in pulmonary inflammation and potential implications 
for CF lung disease 
Traditionally, most research in the CF field focused on the role of NE while in vivo 
studies on other proteases remain limited. The functions of proteases are defined by 
their substrates which themselves are spatially and temporally organized within cells and 
tissues. In vitro studies may identify substrates while an in vivo evaluation of proteases is 
essential to determine their function in health and disease.  
MMP-9 has been implicated in regulating cytokine and chemokine potency with different 
effects between murine and human homologues. Human MMP-9 cleaves IL-8 and 
thereby potentiates its chemotactic activity for neutrophils. In humans and mice, MMP-9 
converts pro-IL-1β into its active form [94]. Murine MMP-9 cleaves and potentiates LIX 
while human MMP-9 has several cleavage sides on the human homologue CXCL5 
(epithelial derived neutrophil activating protein-78, ENA-78) which leads to transient 
activation and subsequent inactivation [29, 155]. In addition, MMP-9 activity contributes 
to the generation of small peptides, PGP, by degrading collagen. These are termed 
matrikines and have chemotactic properties for neutrophils by binding to CXCR1 and 2 
[45, 166]. MMP-9 may activate latent transforming growth factor (TGF)-β [175]. This 
might be of interest since polymorphism increasing TGF-β expression have been 
associated with more severe CF lung disease [27, 75]. TGF-β was shown to be a very 
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potent neutrophil chemoattractant and therefore might aggravate inflammation in CF lung 
disease [10].  
The hypothesis that MMP-9 might assist in leukocyte infiltration may originate from its 
ability to degrade basement membrane type IV collagen. Nevertheless, an involvement 
of MMP-9 in leukocyte recruitment in vivo is still controversial [8, 32]. Also anti-
inflammatory functions have been proposed e.g. limiting macrophage recruitment by 
cleaving intercellular adhesion molecule receptor integrin β2 (CD18) [153]. Of note, anti- 
and pro-inflammatory effects of MMP-9 seem to be context dependent even when 
studied in similar models [17, 99].  
MMP-9 degrades various ECM proteins, e.g. fibronectin or laminin, and similar to all 
neutrophil serine proteases also digests elastin [115]. Increased NE or MMP-9 activity 
have been linked to an aberrant ECM remodeling and impaired regeneration of lung 
parenchyma in a model for ventilator-induced lung injury [58, 59]. Upon epithelial cell 
damage, MMP-7 and MMP-9 expression is detected in regenerating lung tissue [115]. 
MMP-9 is found in migrating basal cells and wound repair can be blocked with MMP-9-
specific antibody treatment. The effect of MMP-9 on respiratory epithelial 
pathophysiology is less well studied. MMP-9 activated pro-IL-1β can induce MUC5B 
expression in airway epithelial cells [44, 157]. This suggests that increased MMP-9 
activity might contribute to airway mucus obstruction in CF lung disease.  
Nevertheless, the potential opposing effects of MMP-9 activity in modulating leukocyte 
chemotaxis, ECM degradation and wound repair illustrate that in vivo studies are needed 
to determine the role of MMP-9 in the pathogenesis of CF lung disease. 
1.4.3.1 Correlation of MMP-9 levels with clinical parameters in CF lung disease 
Several studies measured MMP-9 levels either in sputum or BAL fluid and related those 
to acute pulmonary exacerbations, bacterial colonization, lung function and disease 
severity in CF patients. Most studies focused on soluble MMP-9 protein levels. A study 
by Delacourt et al. reported that MMP-9 activity is elevated in CF patients with acute 
exacerbations compared to asthma patients and detected a correlation with type IV 
collagen degradation products in sputum supernatant [30]. MMP-9 levels were correlated 
with elevated neutrophil degranulation markers. In stable CF patients, MMP-9 activity 
showed an inverse correlation with lung function parameters (FEV1% and forced vital 
capacity %). No association of MMP-9 activity and pulmonary bacterial burden was 
determined [30]. Other studies detected elevated sputum MMP-9 levels either during 
exacerbations but also in CF patients with stable lung disease [63, 104]. A study by 
Sagel et al. showed an imbalance between MMP-9 and TIMP1 and found an inverse 
correlation with FEV1% in CF patients with stable disease [135]. Of note, not all studies 
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reported a relation between MMP-9 levels and disease severity or progression in CF 
patients [46, 136]. In a prospective study over three years various inflammatory sputum 
biomarkers were measured including MMP-9, TIMP1, IL-1β, neutrophil counts and NE 
and associated with lung function changes in CF patients [136]. Only NE, total neutrophil 
counts and IL-1β showed a significant correlation with decline in FEV1 in CF patients. 
MMP-9 concentration was elevated but not changed over the studied period.  
Further studies in CF patients detected higher MMP-9 levels in BAL compared to 
controls [126]. MMP-9 correlated with higher lactoferrin concentrations which indicates 
that neutrophils were the main source of MMP-9 in the studied CF cohort.   Recently, 
Garrat et al. reported that NE concentration, neutrophil counts and MMP-9 levels 
correlate with each other in BAL fluid of pre-school CF patients [48]. Moreover, higher 
abundance of MMP-9 in BAL fluid correlated with the progression of bronchiectasis in CF 
patients [48]. 
These correlative studies suggest that MMP-9 may promote CF lung disease. It is 
important to note that correlation of protease activity with clinical parameters may be of 
value to quantify the risk for patients or to predict clinical outcome. However, additional 
studies are needed to carefully determine the contribution of candidate proteases to 
pathologic signs in model organisms of CF lung disease.  
1.5 βENaC-Tg mice as model for the study of CF lung disease 
Mice deficient for CFTR do not show a lung phenotype resembling lung disease of CF 
patients [143]. Mice with lung specific overexpression of the β-subunit of ENaC were 
generated to mimic human CF lung disease [89]. In healthy airways, CFTR limits ENaC-
mediated Na+ absorption and crucially regulates ASL ion and volume homeostasis [91]. 
Lack of functional CFTR, e.g. by ΔF508 mutation, leads to ASL volume depletion and 
thickened airway mucus (see above).  
1.5.1 βENaC-Tg mice phenocopy key characteristics of CF lung disease 
The club cell secretory protein (CCSP) promotor driven overexpression of the βENaC-
transgene (βENaC-Tg) in mice is sufficient to cause an increased club cell-mediated Na+ 
absorption which results in a reduction of ASL volume, slows mucociliary clearance and 
initiates a spontaneous neutrophilic inflammation [89, 92]. βENaC-Tg mice suffer from 
airway mucus plugging which causes an increased neonatal mortality [66, 92]. 
The trigger of inflammation in the absence of bacterial infection in early CF lung disease 
remains unknown [69]. Studies in βENaC-Tg mice highlight hypoxic epithelial necrosis 
associated with airway mucus obstruction as potential mechanism to cause sterile 
inflammation [43, 86]. Increased pulmonary levels of cytosolic DAMPs, in particular IL-
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1α, were similarly reported for neonatal βENaC-Tg mice and young CF patients [43, 
102]. IL-1α-IL-1 receptor signaling induces subsequently pro-IL-1β expression [43, 80]. 
Pro-IL-1β is typically activated by inflammasome-associated caspase-1 [80]. The stimuli 
for inflammasome assembly are divers and include bacterial components. The resulting 
inflammatory response is predominantly carried by T-helper cell type 2 (Th2) signature 
cytokines e.g. IL-13 in βENaC-Tg mice. Alternative activated macrophages and epithelial 
cells secret high amounts of eotaxin, KC and MIP-2 which mediates the recruitment of 
eosinophils and neutrophils into the lungs of βENaC-Tg mice [89, 92].  
In parallel, goblet cells increase in number and express high levels of mucins i.e. 
Muc5ac, Muc5b and Muc4 [92]. The persistent inflammation leads to emphysema 
formation in distal lung parenchyma of βENaC-Tg mice. The structural tissue damage 
alters inspiratory capacity, lung compliance and other lung function parameters [92]. In 
summary, βENaC-Tg mice represent a phenotype which shows key characteristics of 
early CF lung disease i.e. ASL depletion, mucus obstruction and inflammation [179].  
1.5.2 Characterization of NE activity and NE deletion in βENaC-Tg mice 
βENaC-Tg mice have proven to be a valuable model for studying the pathogenic 
contribution of proteases to CF-like lung disease [49, 150, 162]. In a previous study, NE 
activity was detected only on the surface of neutrophils while soluble NE was completely 
inhibited in BAL supernatant of βENaC-Tg mice [49]. 
NE deficient βENaC-Tg mice display less pulmonary neutrophilia in the presence of 
elevated KC and MIP-2 levels [49]. Goblet cell metaplasia and mucin mRNA levels were 
substantially reduced while mucus obstruction was unchanged. This suggests that 
ENaC-mediated Na+ absorption was sufficient to cause airway mucus plugs in the 
absence of mucin hypersecretion in βENaC-Tg/NE-/- mice. Further, NE deletion in 
βENaC-Tg mice did not compromise innate immune function since no exacerbation of 
bacterial infection was detected [49]. The NE knockout partially reduced emphysema 
formation. This observation indicates that additional mechanisms contribute to lung 
damage in βENaC-Tg mice and potentially to CF lung disease in humans.  
1.6 Current status for treatment of CF lung disease with 
protease inhibitors 
Currently, no protease inhibitor has been approved for the treatment of CF patients. Only 
few clinical trials have been performed with protease inhibitors in CF patients which all 
targeted NE [107, 123]. Inhalation of A1AT aerosol for 4 weeks reduced sputum 
neutrophil counts, NE activity and P. aeruginosa colony forming units but failed to 
improve lung function in CF patients [51].  
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In another trial, application of a small molecule NE inhibitor AZD9668 for 4 weeks 
reduced urinary desmosine levels and IL-6 levels but did not diminish sputum 
neutrophilia, improve lung function or other clinical outcomes in CF patients [36]. In 
summary, the available data for the treatment of CF lung disease with protease inhibitors 
is limited and conclusion about the therapeutic strategy or their potency cannot be 
drawn. Further studies in model organism are needed to carefully dissect the contribution 
of candidate proteases to pathologic alterations in order to evaluate critical targets in CF 
lung disease.   
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1.7 Aims of the thesis 
The aim of this thesis was to evaluate the role of MMP-9 in the pathogenesis of βENaC-
Tg mice and to target relevant proteases by small molecule inhibitors in preventive 
preclinical trials. Genetic deletion of Mmp9 in βENaC-Tg mice and determination of key 
phenotypic characteristics enabled the inference on MMP-9-dependent alterations in 
mice with CF-like lung disease. The analysis included monitoring of survival, 
determination of pulmonary inflammatory response, assessment of airway mucus 
obstruction and quantification of emphysema severity in WT, Mmp9-/-, βENaC-Tg and 
βENaC-Tg/Mmp9-/- mice.  
First, MMP-9 protein levels were assessed in BAL fluid of WT, Mmp9-/-, βENaC-Tg and 
βENaC-Tg/Mmp9-/- mice using gelatin zymography. A change in survival was inferred by 
comparing observed genotype frequencies in adult mice with those calculated by 
Mendel´s Laws. Furthermore, determining inflammatory cytokines, chemokines and 
leukocyte counts in BAL fluid enabled the detection of differences in inflammatory 
cytokine profile and pulmonary leukocyte infiltration in WT, Mmp9-/-, βENaC-Tg and 
βENaC-Tg/Mmp9-/- mice. Assessment of expression of secreted airway mucins Muc5b 
and Muc5ac by qRT-PCR, together with morphometric analysis of mucus content in main 
bronchi in histologic sections enabled the evaluation of airway mucus obstruction. 
Additional analysis of goblet cell metaplasia in airway sections and quantification of 
goblet cell marker expression complemented the analysis by determination of airway 
epithelial alterations. Moreover, lung volume measurement and morphometric 
quantification of distal airspace enlargement in tissue sections were used to elucidate 
changes in emphysema severity in βENaC-Tg compared with βENaC-Tg/Mmp9-/- mice 
and littermate controls.  
Lung function measurements were compared in NE and MMP-9 deficient βENaC-Tg 
mice to assess a potential overlap in the impact of NE and MMP-9 on lung tissue 
mechanics. Based on these findings, a treatment strategy was developed for a 
preventive therapy in newborn βENaC-Tg mice with small molecule protease inhibitors. 
Preclinical studies with the NE inhibitor sivelestat in neonatal βENaC-Tg mice and WT 
littermates were performed and evaluated by assessment of airway mucus obstruction, 
leukocyte counts in BAL fluid and distal airspace enlargement. Furthermore, different 
drug application routes were studied to assess the concept of systemic sivelestat 
treatment to reduce proteolytic lung damage in chronic neutrophilic pulmonary diseases.  
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2 Materials and Methods 
2.1 Experimental animals 
All mouse experiments were approved by the Regierungspräsidium Karlsruhe. Mmp9-/- 
(B6.FVB(Cg)-Mmp9tm1Tvu/J, Jackson laboratories, Bar Habour, ME, USA) [161], NE-/- 
(Jackson laboratories, Bar Habour, ME, USA) mice were intercrossed with βENaC-Tg 
mice [89] to generate WT, Mmp9-/-, βENaC-Tg, βENaC-Tg/Mmp9-/- and NE-/-, βENaC-
Tg/NE-/- mice. NE deficient mice had been backcrossed for >12 generation and Mmp9 
deficient mice for at least 6 generation to a C57BL/6 genetic background. Mice were 
housed under specific pathogen-free conditions with free access to chow and water and 
12h day/night cycle. The characterization of MMP-9 and NE deficient βENaC-Tg mice 
was performed in adult 6 to 8 week-old mice and preclinical trials in newborn mice WT 
and βENaC-Tg mice.  
2.2 Genotyping 
Tail biopsies were boiled at 95°C in 100 µl alkaline lysis reagent  (25 mM NaOH, 0.2 mM 
EDTA, pH 12; Sigma Aldrich, Schnelldorf, Germany) for 40 min. Samples were put on 
ice for 2 min and 100 µl neutralizing reagent was added (40 mM Tris‐HCl pH 5). The 
supernatants containing DNA were used for polymerase chain reaction (PCR) using 











CTT CCA AGA GTT CAA CTA CCG 






GGA ACT TCG TCA TGT CAG CA 
WT reverse TGC ACA GAG AAG GTC TGT CG 








GTG GGA CCA TCA TAA CAT CAC A 
WT reverse CTC GCG GCA AGT CTT CAG AGT A 
KO forward CTG AAT GAA CTG CAG GAC GA 
KO reverse ATA CTT TCT CGG CAG GAG CA 
 
Genotype was confirmed by monitoring the band pattern of the PCR products after 
agarose gel electrophoresis.  
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2.3 Bronchoalveolar lavage and differential cell count  
BAL of mouse lungs and differential cell count (DCC) were performed as previously 
described [92]. Mice were anaesthetized by intraperitoneal injection of ketamine (120 
mg/kg body weight) (Bremer Pharma GmbH, Warburg, Germany) and xylazine (16 
mg/kg) (cp-pharma, Burgdorf, Germany) and sacrificed by incision in the abdominal V. 
cava inferior. Diaphragm and thorax were resected and the left main bronchus was 
ligated to separate the left pulmonary lobe.  
Bronchoalveolar lavage was performed with the four right pulmonary lobes. Through a 
tracheostoma a calculated volume (bodyweight (g) x 17.5 µl) of sterile phosphate 
buffered saline (PBS, Gibco, Thermo Fisher Scientific, Darmstadt, Germany) was 
applied. The adjustment of BAL volume was necessary to account for developmental 
differences in lung size and accurately reflects the total inspiratory capacity until adult 
hood is reached [77]. PBS was gently inserted and withdrawn three times using a 1 ml 
syringe. The recovered BAL fluid was centrifuged at 600 x g to pellet the containing 
mucus plugs and cells. Supernatant were frozen at -80 °C and BAL cell number was 
determined with a Neubauer chamber.  
30,000 cells of the BAL pellet were centrifuged on a glass slide using a cytospin, dried 
and stained 3 min with May-Grünwald (1:1) (Merck, Darmstadt, Germany) and 7 min with 
Giemsa (1:10) (Merck, Darmstadt, Germany) solution for differential cell count. Cell types 
were identified according to their size, nuclear shape and staining properties. A total of 
400 cells were counted to obtain the percentage of each cell type in the BAL fluid. 
Counts of each cell type per volume (cells/ml) were calculated with the total collected 
BAL volume and the determined total cell number in BAL fluid.  
2.4 Gelatin zymography 
Principle  
Gel zymography can be used to monitor enzyme or inhibitors amounts in solution [71, 
156]. The technique is mostly confined to assess protease levels but also other enzymes 
e.g. chitinases can be detected with a modified protocol [148]. Common principle is that 
enzyme activity converts a substrate, which is detected in a second step. In gelatin 
zymography denatured collagen is co-polymerized in a normal sodium dodecyl sulfate 
(SDS) containing polyacrylamide gel. After SDS polyacrylamide gel electrophoresis 
(PAGE) under non reducing conditions, the denaturing SDS is washed out which 
enables the gelatinases to refold to their native conformation and regain activity. 
Refolding is thought to lead to activation of the gelatinase pro-forms. By incubation at 
37°C for several hours gelatin in the gel is degraded which can be detected in a second 
step by coomassie staining of the gel. In summary, the gelatinases are separated 
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according to their size during SDS page and pro- and active form appear as blank 
bands, where gelatin was digested, in the coomassie stained gel. Gelatin zymography 
has a sensitivity in the low pg range for active MMP-2 or MMP-9. Gel zymograms do not 
represent the actual enzyme activity in the sample as endogenous inhibitors are 




Figure 2.1: Principle of gelatin zymography. Schematic example of a coomassie 
stained gelatin zymography gel. The upper two white (not stained) bands in the lane of 
the BAL sample represent pro- and active MMP-9 and the lower pro- and active MMP-2. 
On molecular level (inset) pro-MMPs become activated after refolding and dislocation of 
their inhibitory pro-peptides. Activated pro- and active forms of MMPs digest 
incorporated gelatin within days of incubation at 37°C. In coomassie stained gels, spots 
of gelatinase activity become visible as clear bands.  
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Bovine type B gelatin (Sigma Aldrich, Schnelldorf, Germany) was dissolved at 37-56°C in 
water and copolymerized at a concentration of 0.2 % in a 10 % polyacrylamide gel (0.75 
mm thickness). As standard 2 ng/µl of recombinant murine pro-MMP-9 (R&D Systems, 
Minneapolis, MN, USA) were diluted in 90 µl TCNB buffer (Tris 50mM, CaCl2 10 mM, 
NaCl 150 mM, Brij35 0.05%, Sigma Aldrich, Schnelldorf, Germany) and activated with 10 
µl 10 mM amino-phenyl mercuric acetate (APMA, final 1mM; Sigma Aldrich, Schnelldorf, 
Germany) for 2 h at 37°C. Activated MMP-9 or BAL samples were incubated > 10 min 
with 4 x Laemmli buffer (Biorad, Munich, Germany) without reducing agent at room 
temperature. SDS PAGE was performed at 140 V and 15 mA per gel for 3-4 hours at 4 
 
Reagent Concentration Volume (µl) 
ddH2O  926.5 
Tris-HCl pH 6.8 0.5 M 378 
SDS 10 % 15 
acrylamide-bisacrylamide 40 % 148.5 
TEMED  3 
APS 10 % 30 
Total volume: 1500 µl 
Reagent Concentration Volume (µl) 
ddH2O  1859 
Tris-HCl pH 8.8 1.5 M 666 
SDS 10 % 40 
acrylamide-bisacrylamide 40 % 1000 
gelatin 2 % 400 
TEMED  5 
APS 10 % 30 
Total volume: 4000 µl 
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°C. Subsequently, gels were rinsed with ddH2O and incubated with renaturing buffer (2.5 
% Triton X100; AppliChem, Darmstadt, Germany) twice for 0.5-1 h while rocking at RT. 
After rinsing the gels with ddH2O and they were transferred into development buffer (Tris 
50 mM pH 7.5, CaCl2 5 mM, ZnCl2 1 µM, 0.01 % NaN3) for 30-45 min under gentle 
agitation. Gels were placed in fresh development buffer and incubated for 38-42 h at 
37°C. For visualizing gelatin degradation, gels were rinsed with ddH2O and stained with 
coomassie R250 solution (5 % (v/v) methanol, 10 % (v/v) acetate, 0.5 % (w/v) 
Coomassie R250; Carl Roth, Karlsruhe, Germany) for 1 h. Gels were destained with 40 
% methanol and 10 % glacial acetate (Carl Roth, Karlsruhe, Germany) for 2 - 15 h at RT 
until bands of the protein size standard (Precision Plus Dual color standard, Biorad, 
Munich, Germany) and clear bands of gelatinase activity were visible.  
2.5 Lung histology  
Structural damage was assessed in hematoxylin eosin (HE) stained sections of distal 
lung tissue by stereological methods i.e. mean linear intercept and destructive index.  
For quantification of mucus obstruction and goblet cell metaplasia in the airways Alcian 
blue periodic acid Schiff (AB-PAS) stained sections of the left main bronchi were 
evaluated to determine the mucus volume density or goblet cell counts. 
2.5.1 Fixation, Embedding and sectioning 
The lavaged right lung was ligated under a constantly applied pressure of 25 cm column 
of 4 % paraformaldehyde (PFA, neutral buffered; Fischar, Saarbrücken, Germany). The 
left lung was ligated and not lavaged to preserve mucus plugs. Right and left ligated 
lungs were immersion fixed with neutral-buffered PFA at 4°C overnight. Lungs were 
washed in PBS three times each three minutes and non-lung tissue was removed. The 
inflated right lung was used for lung volume measurement (see below). For storage, 
lungs were kept at 4°C in 70 % ethanol (Carl Roth, Karlsruhe, Germany). 
Lung lobes were separated and right lobes` hilus regions were cut to create an even 
plane for sectioning. Apical left lobe was removed to ensure orientation during 
embedding. All lobes were dehydrated in embedding cassettes (Sanowa, Leimen, 
Germany) by increasing ethanol concentration from 70 % to 2 x 96 % ethanol for 30 min, 
twice in 100 % ethanol for 45 min then followed by overnight incubation in 100 % xylene 
(Carl Roth, Karlsruhe, Germany). Embedding cassettes containing the lungs were placed 
in 55 °C warm dissolved paraffin and incubated under an applied vacuum for 2 h and 1 h 
at atmosphere pressure. The single left lobe or all four right lobes were placed in 
separate molds containing 1 mm solidified paraffin and subsequently filled with 65 °C 
paraffin (Paraplast, Carl Roth, Karlsruhe, Germany) using an embedding station (Leica 
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EG1150H, Leica Microsystems, Nussloch, Germany). Paraffin embedded lungs were left 
at 4°C for >16 h before sectioning.    
Paraffin blocks were cut with a microtome (Leica Microsystems, Nussloch, Germany) in 
5 µm sections for measurement of mucus obstruction and structural lung damage. To 
obtain single cell layer slices, 1.5 µm sections were prepared for goblet cell 
quantification.  
2.5.2 Lung volume measurement 
For the assessment of histological parameters the organ size is relevant. The volume 
displacement method [140] enables the detection of organ volume by submerging the 
lung in PBS and detecting the weight change of the container on a balance. Attached 
tissue and excess liquid is removed from the inflated, fixed right lung lobes. The right 
lung is submerged in PBS and kept in place with a thin wire without touching the 
container wall or bottom (Figure 2.2). The weight is recorded which is a direct estimate of 
the replaced volume by the lung. 
 
 
Figure 2.2: Experimental setup for lung volume measurement. A glass beaker is 
filled with PBS (V1), placed on a balance and a wire is positioned in the container. The 
volume increases (V2) with the submerged lung which is detected by an increased weight 
on the balance.  
By using a wire for submerging the floating lung the difference in density of the lung and 
liquid is compensated by outside force. Therefore, the lung volume is calculated with the 
density of PBS (~1 g/cm3) and the weight before and after submersion. 
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1) ρ = V1/m1 = (V1+V2)/(m1+m2)  
2) V2= ρ*m2 
Thus, according to equation 2) is the lung volume (V2) equal to the measured mass (m2) 
multiplied with the density of PBS.  
ρ = density 
V1 = volume before submerging the organ 
V2 = volume of the organ = volume of the displaced liquid 
m1, m2 = mass of the liquid (1) and displaced liquid (2) 
2.5.3 HE and AB-PAS staining 
The sections were deparaffinized 2 x 10 minutes in xylene and rehydrated 2 x 5 minutes 
in 100 % ethanol, 2 x 2 minutes in 96 % ethanol, 2 min in 70 % ethanol and finally rinsed 
twice in ddH2O. Right lung sections were stained with hematoxylin Gill’s 3 (Sigma 
Aldrich, Schnelldorf, Germany) and eosin G (Carl Roth, Karlsruhe, Germany). Blue 
hematoxylin binds DNA while positively changes acidophilic structure, e.g. cytoplasm or 
collagen, interact with light red eosin dye. For AB-PAS staining, slides with section were 
rehydration and placed in Alcian Blue solution (Sigma Aldrich, Schnelldorf, Germany) for 
30 minutes followed by 5 minutes in periodic acid (Sigma Aldrich, Schnelldorf, Germany) 
and 15 minutes Schiff´s reagent (Sigma Aldrich, Schnelldorf, Germany). Acidic 
saccharides, e.g. sulphated or sialic acid containing mucins, are stained by Alcian blue 
while neutral carbohydrates react with the subsequent PAS reagent and can be detected 
in magenta colour. As a result, neutral basement membrane proteoglycans are stained 
with magenta colour while airway luminal mucus and goblet cells contain both blue and 
magenta stained mucins.    
 
2.5.4 Quantification of structural lung damage by measurement of mean 
linear intercepts and destructive indices  
Images of HE stained lung sections were taken at 16x magnification with an inverted 
microscope (Olympus IX-71 microscope (Olympus, Hamburg, Germany) equipped with a 
camera (DP73; Olympus, Hamburg, Germany) and analyzed using Cell F imaging 
software (Olympus, Hamburg, Germany).  
For mean linear intercept (MLI) measurement a total of 10 images per mouse were 
analyzed. On the photograph 4 parallel lines were placed with the same length as the 
image. The intersecting points of the line with alveolar walls were counted for two lines. 
The total counts of intersections were divided by the length of the two lines. Thereby, the 
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mean linear intersection distance or intercept was obtained. This parameter can be 
regarded as approximation of the mean size of a terminal respiratory structure i.e. 
alveolus and alveolar duct.  
Destructive index (DI) is a measure of the apparent emphysema severity i.e. destruction 
of alveolar structure. A 45 µm x 40 µm grid of points is overlaid on an image of alveolar 
tissue. The points are classified as lying in a destructed or normal area. The criteria for 
determination of the region directly surrounding or adjacent to the point as destructed are 
a) at least two interruptions in alveolar walls or b) at least two isolated parenchyma islets 
or c) presence of emphysematous lesions within the area [134]. The DI is calculated as 
the ratio of the number of destructed point and total point counted (normal + destructed). 
For each animal a minimum of 300 points were evaluated. 
2.5.5 Quantification of mucus obstruction by mucus volume density and 
goblet cell counts 
Stereological methods are used to infer information on 3D structures from 2D 
measurements. A volume density is the ratio of the object volume e.g. mucus and to the 
volume of the whole structure e.g. airway [180]. Volume densities can be directly derived 
from histological sections by measurement of the area of the mucus covering surface in 
the section divided by the area of the whole airway. Harkema et al. established a slightly 
modified parameter called mucus volume density which is defined as [56]:  
3) VS= VV/SV . 
Equation 3) can be converted to: 
4) VS = AM/AA *VA/SA  . 
VS = mucus volume density  
VV = Volume of mucus/ volume of airway = volume density 
SV = airway covering surface area/volume of airway 
AM = area covered by mucus 
AA = area airway 
VA = Volume of the airway 
SA = surface area of the airway 
The relationship between surface volume density SV to boundary length BA is given by:  
5) SV = SA/VA= 4/π BA/AA. 
BA = length of boundary of whole structure = length of airway basal lamina  
Formula 4) and 5) can be transformed to [180]:  
6) VS = AM/BA * π/4. 
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The parameters in equation 6) can be obtained in 2D sections. The mucus volume 
density VS has the unit: nl/mm
2. Airway mucus volume density was measured in AB-PAS 
stained sections of the left proximal main bronchi. Image analysis of airway section 
included manual subtraction of the airway surrounding structures, image conversion to 
gray scale and threshold setting. Mucus covering area, total basement membrane or 
apical epithelial lumen boundary length was used for calculation of mucus volume 
density with formula 6).  
Goblet cells were counted in 1.5 µm AB-PAS stained airway sections and values were 
normalized to basement membrane length. 
2.6 Cytokine measurement with enzyme linked immunosorbent 
assay and cytometric bead array 
The murine chemokine KC (synonym: mCXCL1) and the cytokines IL-1α, IL-1β, IL-13 
were measured in BAL supernatant using cytometric bead array (CBA) kits (BD 
Biosciences, Heidelberg, Germany) according to manufacturer´s instructions. The 
concentration of MIP-2 (synonym: mCXCL2) and LIX (synonym: mCXCL5) and murine 
TIMP-1 was determined in BAL supernatant by enzyme linked immunosorbent assay 
(ELISA) (R&D Systems, Minneapolis, MN, USA).  
2.7 Semi-quantitative reverse transcription-PCR for gene 
expression studies 
2.7.1 RNA extraction from mouse lung with Trizol 
The left lung was transferred into 15 ml Falcon tube containing 1 ml of Trizol (Thermo 
Fisher Scientific, Darmstadt, Germany) and homogenized with a rotor-stator (IKA, 
Staufen, Germany). The sample was left for 20 minutes at room temperature for cell 
lysis. For phase separation 200 µl chloroform (Sigma Aldrich, Taufkirchen, Germany) 
were added and incubated for 3 minutes at room temperature. After centrifugation at 
12,000 x g for 10 minutes at 4°C the upper aqueous phase was transferred in 1.5 ml test 
tubes (Eppendorf safe-lock tubes, Eppendorf, Hamburg, Germany). For total RNA 
precipitation 500 µl isopropanol (100%) was added, mixed and incubated for 10 minutes 
at room temperature. By centrifugation at 14,000 x g for 10 minutes at 4°C RNA was 
pelleted and subsequently washed with 75 % ethanol and air dried. The dry pellet was 
resuspended in RNAse-free water and the concentration and quality was measure in a 
photometer (DeNovix, DS-11 Spectrometer, DeNovix Inc, Wilmington, USA) according to 
Lambert-Beer´s law. 
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2.7.2 cDNA synthesis and quantitative reverse transcription-PCR 
 
To clone a complementary (c)DNA copy of all RNA strands in the sample, random 
hexamer primers were used in reverse transcription mix. The reaction mix for cDNA 
synthesis was prepared as followed:  
Reagent Concentration Volume (µl) 
Hexamer primers 100 nM 2 
dNTPs 10 mM 1 
RNA 1 µg x 
Nuclease free H2O  ad 13 ul 
 
The mixture was heated in a PCR cycler (Veriti, Thermo Fisher Scientific, Darmstadt, 
Germany) to 65 °C for 5 min. Samples were cooled on ice for 2 minutes and a mixture 
was added containing 4 µl FS buffer, 1 µl dithiotreitol (DTT), 1 µl H2O and 1 µl 
Superscript III RT (Invitrogen, Karlsruhe, Germany).  
Quantitative reverse transcription (qRT)-PCR was performed on an Applied Biosystems 
7500 Real Time PCR system (Applied Biosystems, Darmstadt, Germany) with TaqMan 
Universal PCR master mix and inventoried TaqMan gene expression assays were used 
for Muc5ac (Mm01276718_m1), Muc5b (Mm00466391_m1), chloride channel accessory 
1 (Gob5) (Mm01320697_m1), matrix metalloproteinase 12 (Mmp12) (Mm00500554_m1), 
matrix metalloproteinase 8 (Mmp8) (Mm00439509_m1), matrix metalloproteinase 13 
(Mmp13) (Mm00439491_m1), matrix metalloproteinase 2 (Mmp2) (Mm00439498_m1), 
chitinase-like 3 (Ym1) (Mm00657889_mH), secretory leukoprotease inhibitor (Slpi) 
(Mm00441530_g1 ), BPI fold containing family A, member 1 (Splunc1) 













Temperature Duration  
50 °C 2 min 
95 °C 10 min 
95 °C 15 s 
40 x 
60 °C 1 min 
qRT-PCR mix:  
Reagent Volume (µl) 
TaqMan master mix (2x) 10 
Taqman assay 1 
cDNA 1 
H2O 8 
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The amplification cycle of crossing a fixed threshold (CT) for fluorescence intensity was 
determined for the target gene and relative copy number was calculated with the 
efficiencies of the PCR cycle according to Pfaffl et al. [121]. Values were normalized to 
Actb values of the sample and expressed for each genotype as fold-change relative to 
WT samples.  
2.8 Western Blot 
SDS PAGE was done using precast gels (Any kD Mini-PROTEAN TGX Precast Protein 
Gels, Biorad, München, Germany) in a Biorad electrophoresis system at 50 V for 10 
minutes and separation for 1.5 -2 h with 15 mA per gel and 140 V. Gels were blotted on 
PVDF membranes (Trans-blot Turbo, Biorad, Germany) using a Trans-blot turbo transfer 
system (Biorad, München, Germany). Standard blotting settings were chosen with 7 
minutes transfer duration. Membranes were incubated for 1 minute in washing buffer (20 
mM Tris pH 7.5, 150 mM NaCl, 0.1 % Tween 20) and protein free spot on the membrane 
were saturated with blocking solution (5% bovine serum albumin (BSA, Sigma Aldrich, 
Schnelldorf, Germany) in washing buffer) for 1h at room temperature. Blots were washed 
three times for 3 minutes with washing buffer. Primary antibodies were diluted in 10 ml 
blocking buffer. Blots were incubated with the primary antibodies at 4°C overnight under 
agitation. Membranes were washed 2 x 3 minutes and 1 x 5 minutes with washing buffer. 
Horseradish-peroxidase coupled secondary antibodies directed against the host of the 
primary antibody were diluted in washing buffer and incubated with the blots for 1 h at 
room temperature. Excess antibody solution was washed off 2 x 5 minutes and 1 x 10 
minutes with washing buffer. For detection equal volumes, e.g. 1-4 ml, of luminol and of 
hydrogen peroxide solution (Clarity Western ECL, Biorad, Germany) were mix and 
incubated in the dark with the blots for 4 minutes. Chemiluminescence was detected with 
a CCD camera typically for 1-3 minutes (ChemiDoc MP, Biorad, München, Germany).  
 
Primary antibodies:  
Murine antigen Host  Dilution/Concentration Vendor 




Secondary antibodies:  
Antigen Host Dilution Vendor 
anti-rabbit goat 1 : 20000 Sigma Aldrich 
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2.9 Detection of MMP-9 activity with DQ Gelatin  
Gelatin zymography enables the qualitative detection and discrimination of different 
gelatinases according to their molecular weight. Complementary, a soluble fluorescein-
conjugated gelatin reporter was used for the quantitative detection of gelatinase activity 
in BAL supernatant (DQ gelatin EnzCheck; Molecular Probes, Eugene, USA). Detection 
limit of the assay is specified as 7 ng/ml gelatinase concentration.  
For activity measurement in a plate reader (EnSpire, Perkin Elmer, Waltham, USA) 40 µl 
BAL samples or diluted activated MMP-9 (see chapter “Gelatin zymography” 2.4) were 
mixed with 10 µl DQ-Gelatin (125 µg/ml) in black half area 96 well plates (Corning Inc., 
Acton, USA). Fluorescence was excited at 495 nm and emission was recorded at 515 
nm wave length over a period of 1 h. Initial slopes of fluorescence intensity over time 
were calculated as a measure of gelatinase activity in BAL supernatant. In the evaluation 
of MMP-9 activity in BAL supernatant a final concentration of 0.02 ng/µl APMA-activated 
rmMMP-9 was used as positive control. 
2.10 Lung function measurement in mice 
Mice were anaesthetized by intraperitoneal injection of 80 mg/kg sodium pentobarbital 
(cp-pharma, Burgdorf, Germany). Via a cannula inserted into a tracheostoma, the mouse 
was connected to a small animal ventilation apparatus (flexiVent, SCIREQ, Montreal, 
Quebec, Canada.). Under continuous computer controlled mechanical ventilation, mice 
were paralyzed by an intraperitoneal injection of 1.6 mg/kg pancouronium bromide 
(Inresa Arzneimittel GmbH, Freiburg, Germany). For ventilation the following settings 
were chosen: tidal volume of 10 ml/kg body weight, 150 breaths/minute and positive end-
expiratory pressure of 3 cm H2O. Lung tissue mechanics were assessed by different 
maneuvers of various ventilation pressures or volumes performing 4 technical replicates 
for each lung function parameter. 
The inspiratory capacity (IC) is defined as the maximal lung volume obtained with an 
applied pressure which was determined with a gradually increasing pressure up to 30 
mmH2O. Therefore IC values reflect the maximal lung volume during normal inspiration 
which is increased in emphysematous lungs and decreased by fibrotic lung remodeling. 
With a step-wise inflation-deflation cycle protocol with defined pressure (p) or volume (V) 
steps the static compliance and hysteresis area of the pV-loop was determined.  
Compliance is defined as the ratio of volume change to pressure difference and 
therefore can be regarded as the ability of the lung to stretch under a defined pressure 
increase. Low compliance indicates a stiff, rigid lung tissue as seen in lung fibrosis while 
high compliance values typically indicate presence of emphysema. Lung hysteresis in 
the pV loops is observed as the relation between pressure and volume during inspiration 
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differs from that during expiration. During lung inflation higher pressures are needed for a 
defined lung volume than during expiration. The lung hysteresis area is increased with 
the degree of emphysema severity. For the measurement of the dynamic compliance, 
elastance and tissue resistance during a respiratory cycle a sinus-wave with a frequency 
of 2.5 Hz was applied. Resistance was calculated according to the single compartment 
model [6].  
2.11 Treatment with the NE inhibitor sivelestat 
2.11.1 Systemic application via intraperitoneal or subcutaneous injection 
Sivelestat (Ono-5046, M = 456.44 g/mol) (Figure 2.3) is a potent alternative substrate 
inhibitor for NE (IC50 = 49 nM) [67]. PR3 is inhibited to a lower extent and only very weak 
inhibition of CatG has been reported [67, 145]. For systemic application, intraperitoneal 
(i.p.) and subcutaneous (s.c.) injections were performed twice daily (12h cycle) starting 
on the day of birth for two weeks with the endpoint on the 14th postnatal day. Sivelestat 
(Tocris Bio-Techne GmbH, Wiesbaden-Nordenstadt, Germany) was dissolve in 0.9 % 
NaCl (B. Braun Melsungen AG, Melsungen, Germany) to a concentration of 2.5 mg/ml 
with pH adjusted to 7.4-7.5. A single dose of 50 µg/g (body weight) was applied in 20 
µl/g (body weight) either i.p. or s.c. using 30 G syringes (BD Micro-fine, 0.3 ml, 30 G, BD 
Medical, Franklin Lakes, USA). For application of sivelestat or 0.9 % NaCl as control, 
pups were anaesthetized with 3 % isoflurane (Baxter, Deerfield, Ill, USA) in oxygen, 
injected in the lower left abdomen or s.c. in dorsal skin folds and kept at 37°C until 
recovery from anesthesia. Endpoint measurements were differential cell count of BAL 
fluid and lung preparation for histology. 
 
Figure 2.3: Structural formula of the NE inhibitor sivelestat (N-{2-[4-(2,2-
dimethylpropionyloxy)phenylsulfonylamino]benzoyl}aminoacetic acid). Indicated (red) is 
the NE acylating group 2,2-dimethylpropoinat which reversibly binds serine in the active 
center of NE.  
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2.12 Statistics 
Data was derived from at least 3 independent experiments. For statistical evaluation, 
data was analyzed with SigmaPlot version 12.5 software (Systat Software, Erkrath, 
Germany) and is reported as mean ± SEM. For multiple group analysis one-way ANOVA 
was applied with Fisher LSD post-hoc test. Chi Square test was used for genotype 
distribution analysis. Densitometry of western blot was determined with Image J (Image J 
1.48v, NIH, USA). Linear regression was performed for slope determination in MMP-9 
activity measurements and for ELISA standard curves with Microsoft Excel 2010 
(Microsoft, Redmond, USA). Differences were considered significant at P ≤ 0.05.  
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3 Results 
3.1 Evaluation of the pathogenic contribution of MMP-9 to CF-
like lung disease of βENaC-Tg mice 
To evaluate previously described correlation of increased pulmonary MMP-9 levels with 
disease progression in CF patients, genetic deletion of Mmp9 in βENaC-Tg mice was 
used to determine MMP-9-dependent steps in the pathogenesis of CF-like lung disease. 
A heterozygous breeding strategy enabled the phenotype evaluation of adult WT, Mmp9-
/- and βENaC-Tg compared to βENaC-Tg/Mmp9-/- mice. Additionally, lung function 
measurements of NE or Mmp9 deficient βENaC-Tg mice were performed to test the 
independent effects of the respective protease on lung tissue mechanics in adult mice.  
3.1.1 MMP-9 protein levels are elevated in BAL fluid of βENaC-Tg mice  
To assess the levels of MMP-9 in CF-like lung disease, BAL supernatant was analyzed 
by gelatin zymography for simultaneous visualization of pro- and active forms of MMP-9 
and MMP-2 in lungs of WT, Mmp9-/-, βENaC-Tg, βENaC-Tg/Mmp9-/- mice.  
Gelatin zymography of BAL supernatant displayed a predominant band of pro-MMP-9 
(92 kDa) in βENaC-Tg mice that was absent in WT, Mmp9-/- or βENaC-Tg/Mmp9-/- mice. 
Two forms (82 kDa and 75 kDa) of active MMP-9 were visible in βENaC-Tg mice while 
not detected in littermate controls. Pro- (72 kDa) and active MMP-2 (62 kDa) bands were 
observed with approximately similar intensity in all genotypes (Figure 3.1). 
 
Figure 3.1: MMP-9 levels are elevated in BAL supernatant of βENaC-Tg mice. 
Gelatin zymography was performed with BAL supernatant of WT, Mmp9-/-, βENaC-Tg 
and βENaC-Tg/Mmp9-/- mice. Pro-MMP-9 ( ~92 kDa) and its active forms ( ~82 and ~75 
kDa) are present only in BAL of βENaC-Tg mice. Pro- and active MMP-2 ( ~72 kDa and  
~65 kDa, respectively) are detected in all BAL samples in similar abundance.  
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3.1.2 Lack of MMP-9 does not reduce mortality in βENaC-Tg mice 
In previous studies [42, 43, 66, 89, 92], it was reported that impaired mucociliary 
clearance in βENaC-Tg mice results in airway mucus obstruction leading to an increased 
mortality at neonatal age. To investigate the effect of Mmp9 knockout on mortality of 
βENaC-Tg mice, we analyzed the genotype frequency of the cross of heterozygous 
Mmp9+/- mice with βENaC-Tg/Mmp9+/- mice. By comparing the obtained number of 
animals that survived until an age of 6 weeks with the number per genotype calculated 
according to Mendel´s Laws, we deduced the influence of Mmp9 deletion on 
spontaneous mortality in βENaC-Tg mice. The percent of obtained βENaC-Tg mice was 
significantly lower than the calculated value in relation to WT animals. This was not 
prevented by Mmp9 deletion as βENaC-Tg/Mmp9-/- mice presented a similar mortality 
(Figure 3.2 A). Mmp9-/- and WT mice showed similar survival, indicating that MMP-9 
deficiency had no effect on survival. In addition, as a measure of a nutritional status, 
body weight quantification showed no change comparing all genotypes (Figure 3.2 B). 
 
Figure 3.2: Mmp9 deficiency has no effect on mortality or body weight of βENaC-
Tg mice. Comparison of the expected versus obtained genotype frequency (A) of 6 
week-old mice was used to determine mortality of WT, Mmp9-/- , βENaC-Tg and βENaC-
Tg/Mmp9-/- mice (*P < 0.05 compared to WT, calculated by Chi square test, n = 46-136). 
Body weight (B) of 6-8 week-old mice (n = 29-32). 
3.1.3 Inflammation in βENaC-Tg mice develops independently of MMP-9 
To determine the role of MMP-9 in leukocyte recruitment during chronic pulmonary 
inflammation, leukocyte counts in BAL fluid were compared between WT, Mmp9-/- , 
βENaC-Tg and βENaC-Tg/Mmp9-/- mice.  
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Macrophages were the predominant population in BAL fluid of WT or Mmp9-/- mice while 
neutrophils, eosinophils and lymphocytes were almost undetectable in these groups. 
Macrophage counts were not significantly different comparing all genotypes. As 
expected from previous studies [92, 150], βENaC-Tg mice showed spontaneous 
pulmonary inflammation with significantly increased total leukocyte counts in BAL fluid.  
The augmented recruitment of neutrophils and eosinophils accounted for most of the 
increased leukocyte counts in lungs of 6-8 week-old βENaC-Tg compared to WT mice 
(Figure 3.3 A-D). The inflammatory infiltration was not changed by Mmp9 deletion 
suggesting a MMP-9 independent leukocyte influx into the lungs of βENaC-Tg mice. 
Lymphocyte counts reached significantly higher levels in βENaC-Tg and βENaC-
Tg/Mmp9-/- mice compared to WT or Mmp9-/- mice but their total number was 
considerably lower relative to other leukocytes. (Figure 3.3 E).  
 
 
Figure 3.3: Lack of MMP-9 has no effect on leukocyte recruitment in βENaC-Tg 
mice. Differential cell counts of total cells (A), macrophages (B), neutrophils (C), 
eosinophils (D) and lymphocytes (E) in BAL of WT, Mmp9-/-, βENaC-Tg and βENaC-
Tg/Mmp9-/- mice. Counts are shown as (cell counts/ml BAL volume) x 1000. (†P < 0.01, 
‡P < 0.001, compared to WT or Mmp9-/-, n=12-30). 
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Chronic pulmonary inflammation is associated with altered cytokine levels in βENaC-Tg 
mice [92]. To monitor potential alteration in the cytokine profile by Mmp9 deletion we 
assessed BAL supernatant using ELISA and CBA kits. The neutrophil chemokines KC, 
MIP-2 and LIX showed similar levels βENaC-Tg and βENaC-Tg/Mmp9-/- mice that were 
significantly higher compared to controls. This is also reflected in the number of recruited 
neutrophils (Figure 3.3 C, Figure 3.4 A-C). IL-1α and IL-1β levels were not different 
comparing βENaC-Tg and βENaC-Tg/Mmp9-/- mice but significantly elevated in 
comparison to WT and Mmp9-/- mice. IL-13 concentrations showed comparable levels in 
lungs of βENaC-Tg and βENaC-Tg/Mmp9-/- mice that were increased compared to 
controls. This is consistent with the respective eosinophil number detected in BAL fluid 
(Figure 3.3 D, Figure 3.4 F).  
 
Figure 3.4: Lack of MMP-9 has no effect on pro-inflammatory cytokines levels in 
βENaC-Tg mice. Concentrations of KC (A), IL-1α (D), IL-1β (E) and IL-13 (F) were 
measured with CBA kits and MIP-2 (B) and LIX (C) concentrations were determined by 
ELISA in BAL supernatant of WT, Mmp9-/- , βENaC-Tg and βENaC-Tg/Mmp9-/- mice (*P 
< 0.05, †P < 0.01, ‡P < 0.001, compared to WT or Mmp9-/- , n = 10). 
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In addition to IL-13, chitinase 3 like-1 (Chi3l1) was shown to stimulate an alternative 
activation (M2) of macrophage [81]. On transcript levels Chi3l1 was present in 
significantly higher amounts in lungs of βENaC-Tg and βENaC-Tg/Mmp9-/- mice 
compared to controls. Alternative activation of macrophages was confirmed by 
assessment of M2 marker expression. Transcripts levels of the chitinase Ym1 and 
macrophage elastase Mmp12 were significantly upregulated in βENaC-Tg compared to 
WT mice which was not affected in Mmp9 knockout animals (Figure 3.5 A-C).  
In summary, βENaC-Tg/Mmp9-/- mice display no significant change in inflammatory cell 
counts or cytokine profile or alternative activation of alveolar macrophages compared to 
βENaC-Tg mice which suggests that initiation and propagation of inflammation is not 
dependent on MMP-9. 
 
Figure 3.5: Mmp9 deletion has no effect on mRNA levels of markers for alternative 
activated macrophages in βENaC-Tg mice. Lung homogenates were assessed for 
Chi3l1, Ym1 and Mmp12 expression by qRT-PCR. Expression levels are shown relative 
to WT values (*P < 0.05 compared to WT, †P < 0.05 compared to WT or Mmp9-/-, ‡P < 
0.01 compared to WT or Mmp9-/-; n= 9-11). 
3.1.4 Mmp9 deletion partially reduces mucus obstruction while mucin 
expression is not affected in βENaC-Tg mice 
Chronic inflammation and elevated levels of IL-13 and IL-1β are associated with goblet 
cell metaplasia, mucin hypersecretion and mucus obstruction in airways of patients with 
chronic obstructive lung diseases and in βENaC-Tg mice [1, 92, 160].  
We evaluated AB-PAS stained histological sections of proximal main bronchi of βENaC-
Tg, βENaC-Tg/Mmp9-/-, WT and Mmp9-/- mice to determine the effect of Mmp9 knockout 
on airway obstruction. An accumulation of AB-PAS positive material in the airway lumen 
and a thickened epithelium with a high number of goblet cells was present in sections of 
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βENaC-Tg mice (Figure 3.6 A). In contrast, sections from WT animals showed no luminal 
mucus and goblet cells constituted only a minor part of the respiratory epithelium. Mmp9 
deletion had no effect on the histological phenotype compared to WT mice. In βENaC-
Tg/Mmp9-/- mice a lower extent of airway mucus plugging was observed.  
Morphometric analysis confirmed a reduced total airway and intraluminal mucus volume 
density in βENaC-Tg/Mmp9-/- compared to βENaC-Tg mice (Figure 3.6 B-D). Of note, 
this reduction in luminal mucus content was not accompanied by a reduction in goblet 
cell metaplasia and did not result in a higher survival rates in βENaC-Tg/Mmp9-/- 
compared to βENaC-Tg mice (compare also Figure 3.2). WT and Mmp9-/- mice showed 
similar mucus content and goblet cell counts. 
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Figure 3.6: Mmp9 deficient βENaC-Tg mice show reduced airway mucus plugging 
compared to βENaC-Tg mice. Comparison of AB-PAS stained lung sections at the 
level of main bronchi of WT, Mmp9-/-, βENaC-Tg and βENaC-Tg/Mmp9-/- mice for the 
detection of mucus obstruction and goblet cells (A). Counts of AB-PAS positive goblet 
cells per length of airway basement membrane to quantify the metaplastic response of 
respiratory epithelia (B). Mucus obstruction by AB-PAS positive material measured by 
either total airway (C) or intraluminal (D) mucus volume density (*P < 0.05, †P < 0.01, ‡P 
< 0.001 compared to WT or Mmp9-/-, §P < 0.05 compared to βENaC-Tg, n = 10-14; scale 
bar = 100 µm).  
Furthermore, to investigate if Mmp9 deficiency causes a reduced expression of goblet 
cell markers or major mucus components in βENaC-Tg mice, we performed qRT-PCR 
with lung tissue lysates. Expression of Gob5, as a marker for goblet cells, and mRNA 
levels of secreted mucins Muc5ac and Muc5b were significantly higher in βENaC-Tg 
compared to WT or Mmp9-/- mice. Gob5 expression and mucin hypersecretion was not 
reduced in βENaC-Tg/Mmp9-/- compared to βENaC-Tg mice (Figure 3.7). 
In summary, goblet cell counts, goblet cell marker levels and mucin expression were 
similar in βENaC-Tg and βENaC-Tg/Mmp9-/- mice and increased compared to littermate 
controls. Airway mucus obstruction was partially reduced in βENaC-Tg/Mmp9-/- 
compared to βENaC-Tg mice.  
 
 
Figure 3.7: Lack of MMP-9 has no effect on mucin expression in βENaC-Tg/Mmp9-/- 
compared with βENaC-Tg mice. mRNA isolated from whole lung tissue was analyzed 
for goblet cell marker Gob5 (A) and the main secreted airway mucins Muc5ac (B) and 
Muc5b (C) by qRT-PCR (*P < 0.05, †P < 0.01, ‡P < 0.001 compared to WT or Mmp9-/-, n 
= 9-11).  
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3.1.5 Lack of MMP-9 does not reduce lung tissue destruction in βENaC-Tg 
mice 
The measurement lung volume and morphometric assessment of distal lung tissue of 
βENaC-Tg, βENaC-Tg/Mmp9-/- mice and littermate controls were performed to study a 
potential effector role of MMP-9 in emphysema formation. HE-stained sections of distal 
lung parenchyma showed regular tissue structure in WT and Mmp9-/- mice. Alveolar 
structure in βENaC-Tg and βENaC-Tg/Mmp9-/- mice showed similar emphysematous 
lesions i.e. less uniform appearance, fewer septa and more hyperinflated areas 
compared to WT or Mmp9-/- mice (Figure 3.8 A).  
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Figure 3.8: Lack of MMP-9 does not reduce emphysema severity in βENaC-Tg 
mice. Comparison of distal airspace morphology in HE-stained sections of lung 
parenchyma of indicated genotypes (A). Measurement of lung volume (B), and 
evaluation of histology by MLI (C) and DI (D) enabled quantification of emphysema 
severity (†P < 0.01 and ‡P < 0.001 compared to WT or Mmp9-/- , n = 9-32, scale bar = 
100 µm). 
Measurement of the lung volume showed comparable values for βENaC-Tg and βENaC-
Tg/Mmp9-/- mice that were significantly higher compared to littermate controls (Figure 3.8 
B). Furthermore, morphometric quantification of tissue sections displayed similarly 
elevated MLI values in lungs of βENaC-Tg and βENaC-Tg/Mmp9-/- mice confirming a 
significant destruction of alveoli compared to littermate controls (Figure 3.8 C). The 
additional assessment of alveolar structure by DI measurement showed that the number 
of interrupted alveolar walls and of emphysematous lesions was unchanged comparing 
βENaC-Tg and βENaC-Tg/Mmp9-/- mice and was significantly increased in comparison to 
control mice (Figure 3.8 D).  
In summary, βENaC-Tg mice exhibit the previously described destruction of alveolar 
tissue compared to WT mice. Quantification of emphysema severity by lung volume 
measurement and determination of the MLI and DI showed no alteration in βENaC-
Tg/Mmp9-/- compared to βENaC-Tg mice. 
 
3.1.6 Lack of MMP-9 does not improve lung function while NE deletion 
attenuates lung function decline in βENaC-Tg mice 
 
Structural lung damage may alter lung tissue mechanics and therefore impact on lung 
function. Lung function was tested in NE or MMP-9 deficient βENaC-Tg mice to 
determine independent and individual contribution of the respective protease on lung 
tissue properties.  
The pressure-volume curves of βENaC-Tg mice showed significantly higher inflation 
volumes at a given pressure compared to WT mice (Figure 3.9). The excessive lung 
inflation, reflecting emphysematous lung damage, was not changed in βENaC-Tg/Mmp9-
/- mice (Figure 3.9 A). Conversely, NE deletion partially prevented emphysematous 
changes in lung function of βENaC-Tg/NE-/- mice as shown by a reduced lung inflation at 
a controlled pressure compared to βENaC-Tg mice (Figure 3.9 B). 
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Figure 3.9: Mmp9 deletion does not preserve lung function while NE deficiency 
limits lung function decline in βENaC-Tg mice. The pressure-volume curves display 
with the measured slope and inclination the degree of emphysema that is present in 
lungs of WT, Mmp9-/- , βENaC-Tg and βENaC-Tg/Mmp9-/- mice (A) and WT, NE-/-, 
βENaC-Tg and βENaC-Tg/NE-/- mice (B) (†P < 0.01 compared to βENaC-Tg mice, ‡P < 
0.001 compared to WT, NE-/- or Mmp9-/-, n=8-14). 
The inspiratory capacity and static compliance were not changed in βENaC-Tg/Mmp9-/- 
compared to βENaC-Tg mice and both were significantly elevated relative to WT or 
Mmp9-/- animals (Figure 3.10 A,B). NE deficiency in βENaC-Tg mice reduced both 
inspiratory capacity and static compliance compared to βENaC-Tg mice (Figure 3.10 
E,F). Despite a partial reduction in βENaC-Tg/NE-/- mice inspiratory capacity and static 
compliance remained higher compared to WT and NE-/- mice. The hysteresis area of the 
pressure-volume curve was not affected in βENaC-Tg/Mmp9-/- compared βENaC-Tg 
mice (Figure 3.10 C). Conversely, hysteresis area of βENaC-Tg/NE-/- mice reached 
levels close to WT animals while remained increased compared to NE-/- mice (Figure 
3.10 G). Lung tissue elastance was not change in βENaC-Tg/Mmp9-/- compared to 
βENaC-Tg mice but significantly decreased compared to WT or Mmp9-/- littermates 
(Figure 3.10 D). NE deficient βENaC-Tg mice preserved higher tissue elastance relative 
to βENaC-Tg mice although lower compared to WT or NE-/- mice (Figure 3.10 H).  
In summary, Mmp9 deletion had no effect on lung tissue mechanics in βENaC-Tg mice. 
Conversely, βENaC-Tg/NE-/- mice showed improved lung function compared to βENaC-
Results   
40   
Tg mice. This suggests an independent contribution of these proteases to lung function 
decline in mice with CF-like lung disease. 
 
 
Figure 3.10: Lack of Mmp9 results in no improvement of lung function parameters 
in βENaC-Tg mice while βENaC-Tg/NE-/- mice display partially preserved lung 
tissue mechanics. Lung function parameters were measured in anaesthetized, live WT, 
Mmp9-/- , βENaC-Tg and βENaC-Tg/Mmp9-/- mice and WT, NE-/-, βENaC-Tg and βENaC-
Tg/NE-/- mice. Inspiratory capacity, static compliance, area of pressure-volume curve 
hysteresis and elastance are shown for MMP-9 (A-D) or NE (E-F) deficient βENaC-Tg 
mice and littermate controls (†P < 0.01 compared to WT, NE-/- or Mmp9-/-  , ‡P < 0.001 
compared to WT, NE-/- or Mmp9-/- , §P < 0.01 compared to βENaC-Tg mice, $P < 0.05 
compared to βENaC-Tg; #P < 0.05 compared to NE-/- ; n=8-14). 
3.1.7 Lack of Mmp9 does not induce compensatory expression of Mmp2, 
Mmp8 or Mmp13 in βENaC-Tg mice 
Deletion of Mmp9 may lead to a compensatory expression of other matrix 
metalloproteinases which have overlapping substrate specificity. In particular, Mmp2, 
Mmp8, Mmp12 (see Figure 3.5) and Mmp13 are potential candidates previously 
proposed to compensate for Mmp9 deletion in other disease conditions [21, 35, 79].  
  Results 
 41 
Expression of compensatory candidates was assessed by qRT-PCR using RNA isolated 
from lung lysates. Similar to the result shown by gelatin zymography (Figure 3.1), mRNA 
levels of Mmp2 presented a constitutive expression across all assessed genotypes 
(Figure 3.11). Other candidates, Mmp8 and Mmp13, were not differentially regulated on 




Figure 3.11: Effect of Mmp9 deletion on expression of Mmp2, Mmp8 or Mmp13. 
RNA was isolated from whole lungs and expression of Mmp2 (A), Mmp8 (B) and Mmp13 
(C) was quantified by qRT-PCR and normalized to WT values (n = 9-11).  
3.1.8 Secreted MMP-9 is not active in BAL supernatant of βENaC-Tg mice  
Gelatin zymography enables the simultaneous detection of pro- and active MMP-9, 
whereas the actual activity in vivo is modulated by presence of protease inhibitors. We 
used DQ-gelatin, a quenched gelatin-based fluorescence reporter, to assess soluble 
gelatinase activities of MMP-9 and MMP-2 in BAL supernatant of WT, Mmp9-/-, βENaC-
Tg and βENaC-Tg/Mmp9-/- mice. The reporter assay could not detect gelatinase activity 
in any of the BAL fluids of the tested genotypes, while 0.02 ng/µl of activated rmMMP-9 
served as a positive control (Figure 3.12). The lack of gelatinase activity might reflect the 
sensitivity of the reporter assay or more likely depend on the presence of gelatinase 
inhibitors in BAL fluid.  
To test this hypothesis we performed ELISA measurement of the main MMP-9 inhibitor, 
TIMP1, and detected elevated levels in BAL supernatant of βENaC-Tg and βENaC-
Tg/Mmp9-/- mice compared to controls (Figure 3.12 B). To estimate MMP-9 activity in 
vivo, we monitored potential cleavage pattern of the MMP-9 substrate A1AT in BAL 
supernatant. BAL of βENaC-Tg mice showed no detectable cleavage of A1AT. The 
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double band of A1AT likely reflects two glycosylation forms which were also observed in 
WT or MMP-9 deficient mice. Semi-quantitative determination of band intensities 
revealed a trend to higher A1AT levels in BAL fluid of Mmp9-/-, βENaC-Tg and βENaC-




Figure 3.12: Soluble MMP-9 is not active in BAL supernatant of βENaC-Tg mice. To 
monitor gelatinase activity in vitro cleavage of the reporter DQ-gelatin is shown as 
fluorescence change over incubation time with BAL supernatant or activated 
recombinant murine MMP-9 (0.02 ng/µl) (A). TIMP1 levels were measure by ELISA in 
BAL supernatant of WT, Mmp9-/- , βENaC-Tg and βENaC-Tg/Mmp9-/- mice (B). In vivo 
cleavage of A1AT was evaluated by assessment of BAL supernatant in western blot. 
Full-length A1AT is detected in two different glycosylated variants (C). Semi-quantitative 
evaluation of A1AT band intensity in western blots (D) (†P < 0.01 compared to BAL 
samples; ‡P < 0.001 compared to WT, Mmp9-/-; A, n = 5; B, n = 10; C-D, n = 3-5). 
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In summary, although elevated MMP-9 levels are present in BAL supernatant βENaC-Tg 
mice, increased TIMP1 levels prevent soluble gelatinase activity in vitro and in vivo 
indicating a balanced antiprotease-protease ratio in βENaC-Tg mice.  
 
3.2 Treatment studies with the neutrophil elastase inhibitor 
sivelestat 
NE deficiency improved lung function of βENaC-Tg mice. In combination with previous 
studies [49], this suggests that NE, in contrast to MMP-9, is a promising candidate for 
therapeutic intervention. Therefore, preclinical trials using the NE inhibitor sivelestat were 
performed. Newborn WT and βENaC-Tg mice were treated with sivelestat or vehicle (0.9 
% NaCl) either by intraperitoneal or by subcutaneous injection every 12 h for a period of 
2 weeks.  
 
3.2.1 Intraperitoneal application of sivelestat does not prevent onset of 
lung disease in βENaC-Tg mice 
Sivelestat treatment by intraperitoneal (i.p.) injections was well tolerated. Quantification 
of total cell counts in BAL fluid and in particular of neutrophil counts showed no 
difference in sivelestat-treated βENaC-Tg mice in comparison to vehicle controls (Figure 
3.13 A). However, histologic evaluation of AB-PAS-stained lung sections of 2 week-old 
mice showed that sivelestat treatment reduced mucus obstruction in main bronchi of 
βENaC-Tg mice compared to vehicle controls. Moreover, quantification of lung tissue 
damage by MLI measurement in HE-stained tissue sections revealed no significant 
change in sivelestat-treated βENaC-Tg mice compared to vehicle controls (Figure 3.13 
B,C).  
In summary, treatment with the neutrophil serine protease inhibitor sivelestat by i.p. 
injections reduced mucus obstruction but did not prevent the development of chronic 
inflammatory lung disease in juvenile βENaC-Tg mice. 
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Figure 3.13: Intraperitoneal treatment with sivelestat attenuates airway mucus 
plugging but does not prevent inflammation or emphysema development in 
βENaC-Tg mice. Sivelestat (100 mg/kg body weight per day) was applied by 
intraperitoneal injection in newborn mice over a period of 2 weeks. Inflammatory 
leukocyte recruitment was assessed by differential cell count in BAL fluid of WT and 
βENaC-Tg mice treated with sivelestat or vehicle 0.9 % NaCl (A). Lung histology was 
evaluated for airway mucus obstruction by measurement of intraluminal airway mucus 
volume density (B) and for emphysematous changes by determination of mean linear 
intercepts (C). Total = total BAL cells, Mac. = macrophages, Eos. = eosinophils, PMN = 
neutrophils, Lymph. = lymphocytes. (*P < 0.05 compared to WT treated with vehicle or 
sivelestat; †P < 0.001 compared to WT treated with vehicle or sivelestat; #P < 0.05 
compared to WT treated with vehicle; §P < 0.01 compared to βENaC-Tg treated with 
vehicle; $P < 0.01 compared to WT treated with sivelestat; n = 14-20). 
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3.2.2 Subcutaneous application of sivelestat has no impact on disease 
development of βENaC-Tg mice  
To circumvent potential hepatic first-pass effects of sivelestat, we used the i.p. treatment 
protocol for subcutaneous (s.c.) application. After 14 day of s.c. treatment with sivelestat, 
differential cell count of BAL fluid showed an induced recruitment of macrophages, 
eosinophils and neutrophils into the lungs of vehicle treated βENaC-Tg mice which was 
not changed in the sivelestat treated group (Figure 3.14 A). 
 
Figure 3.14: Subcutaneous delivery of sivelestat shows no impact on lung 
pathophysiology of βENaC-Tg mice. Differential cell counts of BAL fluid (A) was used 
to determine the levels of total, macrophages (Mac.), eosinophils (Eos.), neutrophils 
(PMN) and lymphocytes (Lymph.) in sivelestat or vehicle (0.9% NaCl) treated WT and 
βENaC-Tg mice (n= 5-8). Mucus obstruction was quantified in AB-PAS stained airway 
sections by total airway mucus volume density (B) (n= 9-15). Distal lung histology was 
assessed by measurement of mean linear intercepts (C) (n= 8-14). (*P < 0.05 compared 
to WT treated with vehicle or sivelestat; †P < 0.01 compared to WT treated with vehicle 
or sivelestat).  
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Assessment of airway mucus plugging revealed increased mucus obstruction in proximal 
main bronchi of vehicle treated βENaC-Tg mice that was not reduced by s.c. sivelestat 
treatment. Additionally, quantification of lung destruction showed significantly higher 
mean linear intercepts in vehicle treated and no alteration in sivelestat treated βENaC-Tg 
mice (Figure 3.14 B,C). In total, the subcutaneous treatment with sivelestat did not 
prevent or delay the disease onset or severity in 2 week-old βENaC-Tg mice.  
In conclusion, sivelestat treatment of βENaC-Tg mice showed no effect on pulmonary 
inflammation or proteolytic lung tissue destruction. Therefore, further studies are needed 
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4 Discussion 
4.1 Role of MMP-9 in the pathogenesis of βENaC-Tg mice 
Several studies suggest a potential pathogenic role of MMP-9 in inflammatory lung 
diseases (see chapter 1.4.3). However, in vivo studies that investigate MMP-9-
dependent effects in the context of CF lung disease are lacking. The present study 
investigated i) MMP-9-dependent phenotypic alterations in mice with CF-like lung 
disease, ii) the impact of Mmp9 or NE deletion on lung function in βENaC-Tg mice and 
iii) evaluates NE as therapeutic target in preclinical trials with the protease inhibitor 
sivelestat as preventive treatment. 
4.1.1 Elevated MMP-9 levels in BAL fluid in βENaC-Tg mice likely originate 
from activated neutrophils  
In the present study, pro- and active forms of MMP-9 protein were detected by gelatin 
zymography exclusively in BAL supernatant of βENaC-Tg mice (Figure 3.1). Previous 
studies of βENaC-Tg mice showed no differential regulation of Mmp9 or NE mRNA 
levels compared to WT mice [137, 150]. Instead, Mmp12 mRNA levels, as only 
leukocyte-derived protease, were highly elevated in βENaC-Tg mice. Neutrophils 
express Mmp9 and NE only during maturation in the bone marrow and proteases are 
stored in granules [25]. Therefore, neutrophil granules are likely the major source of 
MMP-9 protein in βENaC-Tg mice, since Mmp9 transcription is not induced. Zymography 
also demonstrated that pro-MMP-9 is converted in vivo into its active form in βENaC-Tg 
mice. Numerous proteases are able to cleave pro-MMP-9, of which previously only 
active NE was detected in βENaC-Tg mice [49, 63, 154]. Of note, zymography does not 
display the actual proteolytic activity in vivo since proteases are separated from their 
endogenous inhibitors during SDS PAGE (see Material and Methods 2.4). Instead, 
gelatin zymography enable the detection of gelatinase protein levels in the picogram 
range [156]. The second gelatinase MMP-2 was observed in similar band intensity in all 
genotypes which indicates a constitutive expression and no induction by inflammatory 
stimuli (Figure 3.1, Figure 3.11).  
4.1.2 MMP-9 is not active in BAL supernatant of βENaC-Tg mice 
Presence of active MMP-9 bands in zymograms of CF sputum has been used 
synonymously with MMP-9 activity in some studies [48] although this is misleading. 
Using a soluble gelatin-based reporter enabled the inference on MMP-9 activity in lungs 
of βENaC-Tg mice. In all tested genotypes no free gelatinase activity was detected in 
BAL supernatant (Figure 3.12). Additionally, βENaC-Tg mice displayed higher 
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concentrations of TIMP1 which reflects an intact antiprotease shield and explains the 
lack of free MMP-9 activity. The monitoring of A1AT band pattern by western blot 
revealed no detectable substrate cleavage by MMP-9 in BAL supernatant or in vivo 
(Figure 3.12). Collectively, this indicates that soluble MMP-9 is not active in bronchial 
secretions of βENaC-Tg mice.  
These results are similar to observations monitoring free MMP-12 and NE activity in 
βENaC-Tg mice [49, 150]. Both studies reported an absence of free protease activity in 
BAL supernatant. However, both studies demonstrated a reduction in emphysema 
severity by either NE or Mmp12 deletion in βENaC-Tg mice [49, 150]. In these studies, 
MMP-12 and NE activity was only detected on the surface of macrophages or neutrophil, 
respectively. A recent study supports the view of a pathogenic contribution of cell surface 
NE activity. In this study, Dittrich et al. reported an inverse correlation of FEV1 with either 
free NE activity in sputum supernatant or NE activity on surfaces of neutrophils in CF 
patients [33]. A limitation of the current study is that MMP-9 activity was not assessed on 
the surface of neutrophils in βENaC-Tg mice. This could be addressed by in situ gelatin 
zymography which is also suited to determine gelatinase activity in tissue sections [156]. 
Therefore, a potential surface MMP-9 activity on leukocytes in βENaC-Tg mice cannot 
be excluded. Nevertheless, the present study does not suggest an important pathogenic 
role of a putative cell surface-bound activity of MMP-9 in βENaC-Tg mice.  
4.1.3 Mmp9 deletion reduces mucus obstruction but has no effect on 
mortality in βENaC-Tg mice 
βENaC-Tg mice show an increased mortality mainly within the first two weeks after birth 
[66, 89]. βENaC-Tg expression causes fatal mucus obstruction predominantly in the 
trachea in newborn mice [43, 92]. The analysis of the genotype frequencies of crossing 
Mmp9-/- with βENaC-Tg mice revealed no protective effect by Mmp9 knockout in βENaC-
Tg mice (Figure 3.2). Conversely, MMP-9 deficiency reduced airway mucus obstruction 
in adult βENaC-Tg mice while goblet cell metaplasia and mucin hypersecretion was 
unaffected in βENaC-Tg/Mmp9-/- compared to βENaC-Tg mice (Figure 3.6 and 3.7). This 
suggests that reduced airway mucus obstruction is present in adult but not in neonatal 
βENaC-Tg/Mmp9-/- mice. Furthermore, death causing mucus plugs are found in the 
trachea of neonatal βENaC-Tg mice while the mucus obstruction has been measure in 
main bronchi in the present study. Proximal and distal trachea epithelia were shown to 
differ in cell composition and ion channel expression [103] and the difference might be 
even stronger when comparing trachea and bronchi. This spatiotemporal difference 
might explain the lack of an association between the observed reduction in airway 
obstruction in adult βENaC-Tg/Mmp9-/- mice and neonatal mortality.   
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Reduced airway mucus obstruction in adult βENaC-Tg/Mmp9-/- mice might be a result of 
changed MCC and/or altered airway epithelial ion channel permeability compared to 
βENaC-Tg mice. Alternatively, mucus composition could be altered which changes its 
rheology. DNA and actin, e.g. of necrotic or NETing neutrophils, have a disproportional 
strong effect on mucus viscosity [78]. Although MMP-9 has not been implicated directly 
in NET generation, its association with DNA in NETs has been documented [13]. Also, 
oxidation of mucins, e.g. by oxidative burst of leukocytes, was shown to increase cross-
linking, thereby stiffen mucus polymers and potentially compromising its clearance [177]. 
How MMP-9 may be implicated in these processes is unknown. Previous studies in 
βENaC-Tg/NE-/- mice reported reduced DNA content in BAL, diminished goblet cell 
metaplasia and mucin expression but invariantly increased airway mucus obstruction 
compared to βENaC-Tg mice [49]. ENaC-mediated Na+ currents were unchanged and 
the resulting ASL depletion was sufficient to cause airway mucus obstruction. This was 
also reflected by similar mortality in βENaC-Tg/NE-/- and βENaC-Tg mice. These results 
suggest that alterations in ENaC conductance are the main determinant for the 
development of airway mucus plugging while lower mucin secretion or changes in mucus 
composition, i.e. lower DNA content, are not protective in βENaC-Tg mice.  
Performing electrophysiological measurement of isolated trachea epithelia by Ussing 
chamber could enables direct quantification of potentially altered ENaC-mediated Na+ 
absorption in airway epithelia of βENaC-Tg/Mmp9-/- mice. Complementary measurement 
of MCC by monitoring clearance of fluorescent tracers after instillation or applied directly 
on trachea epithelia could be used to detect differences in mucus clearance between 
βENaC-Tg/Mmp9-/- and βENaC-Tg mice.  
4.1.4 Mmp9 deficiency has no effect on chronic inflammatory lung disease 
in βENaC-Tg mice 
IL-1α is released upon cell necrosis and has been reported as sterile trigger for 
inflammation in βENaC-Tg mice [43]. Further propagation of inflammation involves IL-1β 
signaling. Secreted proteases including MMP-9 were shown to convert pro-IL-1β and 
thereby might contribute to subsequent inflammatory responses [141]. In the present 
study, IL-1α and IL-1β concentrations are similarly elevated in βENaC-Tg and βENaC-
Tg/Mmp9-/- mice (Figure 3.4 D, E). This may indicate a persistent pro-inflammatory 
stimulus by necrotic cells and MMP-9-independent generation of IL-1β e.g. by 
inflammasomes [80]. MMP-9 was shown to be involved in the migration of cultured 
airway epithelial cells in wound healing models [15, 82]. In these models, large wounds 
are induced by NaOH application in vitro which is different to the single cell necrosis 
present in airways of βENaC-Tg mice [92]. An important distinction might be that airway 
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epithelial basement membranes are intact in βENaC-Tg mice. Thus, replacement of 
epithelial cells by basal cells is likely unaffected and not dependent on MMP-9. βENaC-
Tg mice were shown to develop spontaneous pulmonary bacterial infections which may 
potentiate the immune response [49, 86]. In this context, it is worth noticing that Mmp9 
deletion has not been implicated in an impairment of bacterial killing [8, 154].  
Damaged epithelia release cytokines, e.g. IL-33 and IL-13, which initiates wound healing 
and tissue repair [42, 105]. This pathway is predominant in βENaC-Tg mice as illustrated 
by elevated expression of macrophage M2 signature genes [137, 150]. IL-13 
concentrations were similar in βENaC-Tg and βENaC-Tg/Mmp9-/- mice (Figure 3.4. F). 
Alternative activation of macrophages was not changed as indicated by equally elevated 
Mmp12 and Ym1 levels in both genotypes (Figure 3.5.). MMP-9 expression has been 
linked both to M1 or M2 macrophages [114, 139] and therefore cannot be regarded as a 
reliable marker for polarization.    
The resulting inflammatory response in adult βENaC-Tg mice was not affected by Mmp9 
knockout (Figure 3.3 and 3.4). In the presence of raised levels of neutrophil 
chemoattractants no alteration of neutrophil recruitment is observed in the lungs of 
βENaC-Tg/Mmp9-/- mice compared to βENaC-Tg mice (Figure 3.3). Similarly, eosinophil 
and lymphocyte migration was not affected by Mmp9 deletion in βENaC-Tg mice.  
The direct role of MMP-9 in leukocyte recruitment to inflammatory sites is still 
controversial [8, 32]. In vitro studies suggest an involvement of MMP-9 in transmigration 
of eosinophils and neutrophils across artificial basement membranes [31, 108]. Although 
MMP-9 may degrade basement membrane collagen type IV, to date no study using 
protease inhibitors or genetic deletion has conclusively demonstrated the necessity for 
MMP-9 to transverse basement membranes in vivo [72]. Several studies modeling acute 
inflammation reported no difference in neutrophil infiltration into lung, peritoneum or skin 
tissues when comparing Mmp9-/- and WT mice [4, 8, 165]. Interestingly, transgenic 
pulmonary IL-13 expression resulted in enhanced recruitment of neutrophils in Mmp9-/- 
compared to WT mice [79]. In asthma models, it was shown that less leukocytes are 
recruited in Mmp9-/- mice while a different study using the same model demonstrated no 
difference in neutrophil but even higher eosinophil numbers in lungs of Mmp9-/- 
compared to WT mice [17, 99]. A potential difference between these studies might be the 
applied experimental conditions and the used stimuli inducing different levels of acute or 
chronic inflammatory responses. Moreover, lung infiltrating leukocytes transmigrate at 
alveolar capillaries and not primarily at post-capillary venules as in other organs [130]. 
Leukocytes are thought to cross endothelia at tricellular borders where junction proteins 
are discontinuous [72]. Furthermore, IL-1β was shown to alter epithelial resistance and 
IL-13 may promote cellular tight junction disruption [26, 172]. In conclusion, prolonged 
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cytokine exposure may be sufficient to interfere with endothelial and epithelial barrier 
function which may permit MMP-9-independent leukocyte transmigration into airspaces 
in βENaC-Tg mice.  
Chronic inflammation in βENaC-Tg/Mmp9-/- and βENaC-Tg mice lead to a similar degree 
of alveolar destruction as quantified by lung volume measurement and by morphometric 
parameters i.e. MLI and DI (Figure 3.8). The data indicate no crucial contribution of 
MMP-9 to lung morphogenesis or proteolytic destruction during chronic, neutrophilic 
inflammation in βENaC-Tg mice. NE deletion in βENaC-Tg mice reduced emphysema 
severity by approximately 50 % [49]. The hypothesis of MMP-9 as effector of NE activity 
is not supported by the current results. Hence, a contribution of MMP-9 to residual 
emphysema in βENaC-Tg/NE-/- mice is unlikely. A redundancy in the protease web could 
explain the lack of prominent influence of MMP-9 deficiency in βENaC-Tg mice. In fact, 
most Mmp deletions do not result in a notable phenotype which points to functional 
overlap and robustness in the proteolytic system [24, 125]. In βENaC-Tg mice Mmp12 
deletion reduced emphysema but not mucus obstruction or inflammation compared to 
βENaC-Tg mice [150]. Of note, MMP-12 has additional intracellular functions in 
regulating transcription which might also modulate lung disease in βENaC-Tg mice [96]. 
According to the current view versatile interactions between proteases and inhibitors 
constitute the protease web [41]. Identification of node points in the protease web could 
enable intervention in pathophysiologic processes. However, the current and previous 
studies in βENaC-Tg mice point to the involvement of several proteases in parallel 
pathogenic processes leading to similar disease states e.g. emphysema and/or mucus 
obstruction [49, 150]. In addition, overlapping substrate specificity with MMP-9 might be 
sufficient to compensate for genetic deletion of Mmp9 in βENaC-Tg mice. MMP-8 is in 
particular an interesting candidate for compensation. Mmp8 is not upregulated on mRNA 
level in βENaC-Tg/Mmp9-/- mice compared to βENaC-Tg mice (Figure 3.11). However, 
MMP-9 and MMP-8 are both found in secondary granules of neutrophils and therefore 
secreted simultaneously [25]. Furthermore, protease function might differ between 
disease states. Hence, MMP-9 could have essential function in pathophysiological 
processes that are not represented in βENaC-Tg mice in particular during infection with 
CF-related pathogens.  
Alternative protease-independent mechanisms linking activated leukocytes, oxidative 
lung damage and increase epithelial apoptosis to emphysema formation are discussed 
[117].  Structural lung damage may also be induced or enhanced by environmental 
exposures in particular by bacterial infections [5, 127]. In a mouse model of chronic low-
dose LPS exposure an increased count of apoptotic alveolar epithelial cells was detected 
and proposed as underlying cause of emphysema. Of note, MMP-9 deficient mice were 
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not protected from epithelial apoptosis and emphysema formation triggered by LPS 
inhalation [12].  
Alveolar and also airway epithelial damage may also be caused by oxidative stress 
which is associated with an oxidant-antioxidant imbalance [5, 117]. Oxidative stress may 
arise from ROS release by phagocytes during killing of large, indigestible pathogens 
[164]. It has also been suggested that hypoxia contributes to oxidative lung damage by 
impairing oxidant-antioxidant balance and/or generation of ROS from mitochondria [3]. 
Glutathione (GSH), vitamin C and also mucins may serve as oxidant scavengers in the 
lung [117]. In fact, oxidative stress was reported in βENaC-Tg mice as indicated by 
reduced GSH to oxidized glutathione GSSG ratios which could be reversed by 
thiocyanate treatment [18]. In summary, the present study suggests that MMP-9 is not 
directly involved in chronic inflammation or alveolar tissue destruction and residual 
emphysema in NE deficient βENaC-Tg mice might be explained by the activity of other 
proteases, epithelial apoptosis or oxidative lung damage.  
4.1.5 Lung function testing of βENaC-Tg mice indicate no overlapping 
effects of Mmp9 or NE deletion on lung tissue mechanics 
The analysis of lung function in βENaC-Tg/NE-/- and βENaC-Tg/Mmp9-/- mice further 
investigated NE- and MMP-9-dependent pathogenic effects in βENaC-Tg mice. Like NE, 
MMP-9 degrades elastin but also other ECM components e.g. fibronectin, laminin and 
collagen [124, 128]. Elastin and collagen fibers are organized in a complex network 
within the lung which determine the mechanical characteristics [163, 167, 171].  
So far, the individual role of either protease on lung tissue mechanics has not been 
studied in CF-like lung disease. Lack of MMP-9 did not prevent lung function decline but 
NE deletion improved lung function in all tested parameters in βENaC-Tg mice (Figure 
3.9, 3.10). This suggests that MMP-9 does not contribute significantly to NE dependent 
lung disease in βENaC-Tg mice. In reverse, Mmp9 deletion might result in enhanced 
compensatory NE activity. In this case higher proteolytic lung damage would be 
expected in βENaC-Tg/Mmp9-/- compared to βENaC-Tg mice. Hence, invariantly 
increased NE activity in βENaC-Tg/Mmp9-/- mice likely mediates, at least in part, the 
observed lung function impairment similarly to βENaC-Tg mice.  
Histology and lung function measurements showed that βENaC-Tg mice display 
emphysematous, enlarged distal airspaces (Figure 3.8 - 3.10) [92, 150]. This is in 
divergence to CF patients who develop predominantly bronchiectasis. Species-specific 
difference between mice and humans in the anatomical lung structure including bronchial 
size and branching pattern might explain these different observations [92, 132]. It has 
been hypothesized that the lower number of airway branching in mice compared to the 
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human lung might favor a faster distribution of damaging factor from inflamed airways to 
distal alveolar parenchyma in mice [162]. 
In CF patients, several correlative studies with FEV1 measurements as main determinant 
of lung function and MMP-9 levels in sputum have been performed. The first published 
study by Delacourt et al. demonstrated a significant inverse correlation of MMP-9 activity 
in sputum supernatant and FEV1 in clinically stable CF patients [30]. However, NE 
activity was not assessed in this study. In a subsequent study, MMP-9 activity was only 
significantly higher during exacerbations but no association with lung function alterations 
were detected in CF patients [46]. In a study by Sagel et al., an association of lower 
FEV1 with higher MMP-9 protein levels were determined [135]. This result was not 
confirmed in a subsequent prospective study over 4 years by the same group. In 
particular, this study showed that annual FEV1 decline in CF patients with relatively 
conserved lung function correlated with NE but not MMP-9 concentrations in sputum 
[136]. The different detection methods of either MMP-9 protein levels or activity and 
difference in the patient cohort impede a conclusive comparison of the mentioned 
studies. The divergent stage of lung function impairment in the studied CF cohorts and 
the lack of NE activity measurements further complicate the interpretation. Conversely, 
numerous studies reported an association of NE and structural lung damage or lung 
function decline in CF patients [33, 97, 136, 142].  
In conclusion, the current data suggest that NE is directly involved in lung function 
impairment while MMP-9 has a minor role as disease promoting factor in βENaC-Tg 
mice. Therefore, diminished spirometric parameters in CF patients might be essentially 
related to higher neutrophil counts and secretion of NE whereas the concomitant release 
of MMP-9 might be less important. Therefore, the specific inhibition of MMP-9, in 
contrast to NE, is unlikely to be an effective treatment for the lung disease of βENaC-Tg 
mice and potentially of CF patients. 
4.1.6 Comparison of the studies on the role of MMP-9 in βENaC-Tg mice to 
CF lung disease in patients 
The classical concept explaining lung damage and lung function decline in several 
obstructive lung diseases is based on the finding of high concentrations of proteases 
with simultaneously reduced anti-protease levels in bronchial secretions [60, 107, 117, 
136].  
With regard to MMP-9, MMP-12 and NE, endogenous antiproteases completely inhibit 
soluble protease activity in pulmonary secretions of βENaC-Tg mice (see Figure 3.12) 
[49, 150]. This poised protease-antiprotease ratio in βENaC-Tg mice points to a 
significant difference to CF patients, especially in later disease stages. Young CF 
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patients (~ 12 years) showed an induction of TIMP1 protein amount while in adults with 
CF (~ 22 years) TIMP1 protein was depleted from bronchial secretions compared to 
healthy controls [46, 135]. In older patients, as CF lung disease progresses higher 
neutrophil counts in sputum are observed and therefore more secreted NE is detected 
which likely degrades TIMP1 [33, 91, 135]. Adult βENaC-Tg mice show a neutrophil 
percentage in BAL fluid which is more representative of early CF lung disease [69, 92]. 
The ~2- to 7-fold higher ratio of blood neutrophils to total white blood cells in humans 
compared to mice likely contributes to a lower lung neutrophilia in adult βENaC-Tg mice 
compared to CF patients [101]. In young CF patients, higher neutrophil protease levels 
are especially found during bacterial respiratory infections [48]. These exacerbations 
may cause an intermittent disruption of the antiprotease shield in young CF patients 
which is not represented in βENaC-Tg mice.  
Several studies suggest that during chronic inflammation with gradually increasing 
neutrophil counts and associated release of granule contents, NE concentrations may 
exceed antiprotease levels and free NE activity may trigger pro-MMP-9 activation in 
older CF patients [46, 136]. This unopposed protease activity is thought to cause 
structural lung damage by disrupting epithelial function, aggravating airway mucus 
obstruction and further promoting inflammation [107, 159]. In contrast to the current 
study, previous studies in CF patients suggest that unopposed NE and MMP-9 activity 
cause lung tissue damage [48, 142]. Garrat et al. reported that increased MMP-9 levels 
correlated moderately with the progression of bronchiectasis within 12 months in CF 
patients. This correlation was based on MMP-9 protein amount detected by gelatin 
zymography and not activity [48]. Furthermore, the cohort in this study was carefully 
composed of similar group size of patients with NE activity in BAL and those without. 
Secretion of NE-containing azurophil granules require higher stimuli concentrations than 
for MMP-9 containing granules [122]. As expected, MMP-9 protein levels and NE activity 
showed a positive correlation in CF BAL fluid [48]. Therefore, presence of NE activity 
might have been a confounding factor introduced by group sampling in their analysis. In 
mouse models for chronic obstructive pulmonary disease (COPD), MMP-9 deficiency 
had no protective effect in mice with smoke-induced emphysema [4]. Furthermore, 
emphysema severity in COPD patients did not correlate with Mmp9 mRNA levels in lung 
tissue.  
The current study in βENaC-Tg/Mmp9-/- mice questions the role of MMP-9 in CF lung 
disease. However, based on the current results definitive conclusions about a 
pathogenic role of MMP-9 in patients cannot be drawn because several characteristics of 
CF lung disease, e.g. intermittent infections and the degree of neutrophilic inflammation, 
are not be represented in βENaC-Tg mice. The role of NE and MMP-9 and their 
  Discussion 
 55 
interaction during exacerbations could be further studied by challenging βENaC-Tg mice 
with LPS or bacterial pathogens. This might create temporarily disrupted protease-
antiprotease balance. Thereby, unopposed free NE could generate high levels of soluble 
MMP-9 activity and enable the study of the role of MMP-9 during inflammation with high 
neutrophil counts in βENaC-Tg mice. 
 
4.2 Preclinical trials revealed no improvement of key 
characteristics by sivelestat treatment in mice with CF-like 
lung disease 
The studies of NE deficient βENaC-Tg mice suggest that inhibiting NE activity with small 
molecule compounds might delay or prevent lung disease in βENaC-Tg mice. To date no 
protease inhibitor has an approval for the treatment of CF lung disease [123]. In Japan 
and Korea, sivelestat has been approved for the treatment of acute lung injury (ALI) 
associated with systemic inflammatory response syndrome [57]. Sivelestat inhibits two 
major neutrophil serine proteases NE and PR3 while CatG activity is reduced only at 
higher inhibitor concentrations [145]. The performed preclinical trials using sivelestat 
were designed to assess the concept of pharmacologic targeting of neutrophil serine 
proteases in mice with CF-like lung disease.  
Intraperitoneal application of sivelestat resulted in a reduction of mucus obstruction but 
did not reduce inflammation or prevent emphysema development in 2-week old βENaC-
Tg mice compared to vehicle controls (Figure 3.13). The subsequent s.c. study showed 
no improved therapeutic effect compared to i.p. injection of sivelestat in βENaC-Tg mice 
(Figure 3.14). This indicates that hepatic first-pass effects were likely not responsible for 
the inefficiency of sivelestat.  
Nevertheless, the negative results may be related to pharmacokinetic properties of 
sivelestat since in vitro inhibition of NE is well characterized [67]. In the current study, a 
single applied dose (50 mg/kg body weight) exceeded the IC50 for NE (49 nM) by ~ 2200 
fold assuming a uniform distribution within the whole body (see also Methods 2.11.1). Of 
note, the published IC50 [67] is based on in vitro titration and likely differs from in vivo 
values (see below). The pharmacokinetic parameters for sivelestat are not well 
documented in the literature. Treatment of ALI patients with sivelestat requires 
continuous intravenous perfusion over days to assure therapeutic levels [57]. This may 
be related to a short half-life time of approximately 2 hours [98]. At physiologic blood pH, 
sivelestat is present mainly as anion due to the carboxyl groups in its structure (see 
Figure 2.3.). The plasma membrane permeation of sivelestat as charged molecule is 
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likely restricted and in particular diffusion into blood vessels and from blood into 
pulmonary tissue might be limited. During inflammation capillaries become more 
permeable which results in higher plasma content at inflammatory sites. In fact, patients 
with ALI due to systemic inflammation, e.g. sepsis, typically suffer from pulmonary 
edema what explains the effectiveness of sivelestat in this disease condition [19, 57]. In 
studies with murine models of pulmonary diseases the same sivelestat dose as used in 
the current studies achieved therapeutic effects when applied by i.p. injections. In an 
asthma model or ALI model sivelestat treatment reduced pulmonary inflammation and 
goblet cell metaplasia or decreased neutrophil infiltration and alveolar damage, 
respectively [70, 138]. However, in these and other studies an acute inflammatory 
responses was induced in adult mice and sivelestat was applied directly before 
inflammatory stimulation and only for a short study period [62]. The current study 
indicates that the chronic lung disease that develops over the first two weeks in βENaC-
Tg mice could not be reduced by sivelestat treatment. Sivelestat primarily inhibits NE 
and is a less potent inhibitor for PR3 while CatG is not targeted at therapeutic doses. 
Unopposed CatG activity could be an additional explanation for the limited effects by 
sivelestat treatment in βENaC-Tg mice. 
In newborn mice i.p. or s.c. injections are the only practical application methods for 
systemic drug delivery. With a 12 h application cycle in combination with a slow drug 
absorption, in particular after s.c. injection, a prolonged plasma sivelestat concentration 
can be assumed [151].  In general, absorption of water soluble drugs is expected to be 
more rapid after i.p. than with s.c. injections [50]. However, the exact bioavailability 
depends on drug properties and is not published for sivelestat. I.p. injection of sivelestat 
might result in more rapid absorption and higher blood peak levels compared to s.c. 
application. Therefore, higher blood sivelestat levels after i.p. application might partially 
inhibit NE in pulmonary tissue and thereby reducing NE-mediated mucin expression 
[159]. This might explain the diminished mucus obstruction in βENaC-Tg mice treated 
with sivelestat by i.p. injections but not by s.c. application. 
In previous studies, NE was shown to be active solely on the surface of neutrophils in 
βENaC-Tg mice and not in BAL supernatant [49]. Cell surface-bound NE was shown to 
be highly resistant to inhibition by endogenous inhibitors, like A1AT, but also small 
molecular weight inhibitors were less effective in limiting activity of surface-bound NE 
[116]. This may explain the preserved surface NE activity on neutrophils in βENaC-Tg 
mice reported in previous studies [49]. In addition, this observation suggests that 
significantly higher sivelestat concentrations are necessary to fully inhibit neutrophil 
surface-bound in comparison to soluble NE activity. The polar nature of sivelestat 
restricts NE inhibition to the extracellular location and excludes accumulation within 
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primary neutrophil granules prior to secretion. NE is stored in azurophil granules in mM 
concentrations which results upon secretion in a transient mismatch between NE and 
inhibitor concentration [84]. This process, termed quantum proteolysis, predicts NE 
activity in the surrounding of neutrophils even in the presence of high levels of inhibitors. 
Additionally, neutrophils may form an integrin-based seal around contact sites to ECM 
substrates which restricts access of inhibitors to secreted proteases [118, 176]. The 
performed preclinical trial using sivelestat could not reproduce the results of NE deletion 
in βENaC-Tg mice. Lack of NE reduced neutrophil infiltration and emphysema severity 
but had no effect on airway mucus obstruction in adult βENaC-Tg mice [49]. The 
contradictory result of the preclinical sivelestat trial might reflect insufficient sivelestat 
levels in pulmonary tissue to achieve effective NE inhibition in particular on the surface of 
neutrophils. A limitation of the performed treatment studies is that the concentrations of 
sivelestat in lung tissue or blood have not been assessed. Local application by intranasal 
(i.n.) instillation could be performed to enable sufficient pulmonary sivelestat levels.  A 
disadvantage of i.n. instillation is that only low volumes and therefore only low drug 
doses can be applied. MCC in murine airway may prevent sustained pulmonary drug 
levels. In addition, airway mucus plugging in βENaC-Tg mice could also impede 
sivelestat delivery into lower airspaces. 
The difficulty to inhibit NE activity in CF lung disease may be reflected in the low number 
of clinical trials conducted so far. These trials using different NE inhibitors reported only 
limited effects on lung disease in CF patients [36, 51] (see also introduction 1.6). The 
preclinical trials with sivelestat revealed that effective treatment requires inhibitor 
concentrations that are high enough to target neutrophil serine proteases in solution and 
on cell surfaces. To achieve this, a membrane permeable inhibitor e.g. GW311616A [87] 
that may accumulate within azurophil granules of blood neutrophils could be more 
effective. Alternatively, prevention of neutrophil serine protease activation by cathepsin C 
inhibition within bone marrow neutrophils was shown to abrogate levels of all neutrophil-
derived serine proteases without impairing neutrophil recruitment into the lungs [53]. 
Cathepsin C deficiency cause Papillon-Lefèvre syndrome in humans. Main symptoms 
are periodontitis and subsequent loss of teeth at young age [131]. Thus, adverse effects 
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5 Conclusions 
Increased protease activity is thought to contribute to the reported differences in the 
progression of lung disease in CF patients. The evaluation of the role of individual 
proteases as disease promoting factor is crucial for the development of targeted 
therapies to treat CF lung disease. Most research has focused on the neutrophil-derived 
serine protease NE while less is known about the involvement of other proteases. The 
present work elucidates the role of the putative NE effector MMP-9 in βENaC-Tg mice 
and evaluates protease inhibitor treatment as a therapeutic strategy for CF patients.   
Monitoring of MMP-9 protein levels indicated high abundance in BAL fluid of βENaC-Tg 
mice. The further analysis of MMP-9 deficient βENaC-Tg mice showed reduced airway 
mucus obstruction which did not result in lower mortality, nor attenuate inflammation or 
decrease distal airspace enlargement compared to βENaC-Tg mice. Furthermore, 
comparison of lung function in βENaC-Tg, βENaC-Tg/NE-/- and βENaC-Tg/Mmp9-/-mice 
indicated that Mmp9 deletion did not ameliorate lung function parameters relative to 
βENaC-Tg mice while NE deficiency reduced lung function decline. The current data 
demonstrate that the mere presence of MMP-9 in BAL fluid of βENaC-Tg mice does not 
predict a pathological role. In summary, the study indicates that MMP-9 is not a pivotal 
pathogenic factor while NE significantly contributes to lung disease of βENaC-Tg mice.  
Implications of these results were applied and tested in a preventive, preclinical trial 
using the NE inhibitor sivelestat in newborn WT and βENaC-Tg mice. Intraperitoneal 
application of sivelestat reduced airway mucus obstruction but failed to prevent 
inflammation or lung tissue destruction in βENaC-Tg mice. These results may be related 
to pharmacokinetic characteristics of sivelestat or the persistence of inhibitor-resistant 
NE activity on neutrophil-surface or in sequestered locations in lung tissue.  
In summary, the data suggest that Mmp9 deletion does not attenuate lung disease in 
βENaC-Tg mice. To the extent that βENaC-Tg mice resemble CF lung disease, these 
results question the proposed pathogenic role of MMP-9 in patients. The performed trials 
with sivelestat indicate that further treatment studies are needed using compounds with 
improved pharmacokinetic properties to target neutrophil-surface protease activity and to 
translate the findings of protease-deficient βENaC-Tg mice into clinical practice. 
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